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ABSTRACT 
 
 
Free radicals and other reactive oxygen species (ROS) constitute a normal part 
of the intracellular environment. Endogenous enzymes such as catalase, 
superoxide dismutase and the thiol redox systems, glutathione and oxidized 
glutathione, serve as reducing agents to minimize the harm ROS might cause in 
the cell. An excess of ROS, however, can tilt the delicate balance leading to 
oxidative stress. It is now well known that oxidative stress (OS) plays an 
important role in many neurodegenerative disorders such as Parkinson disease, 
Alzheimer’s disease, amyotrophic lateral sclerosis and other disorders with 
neurodegenerative effects, including adrenoleukodystrophy (ALD). 
 
 
Many antioxidants have been studied in an effort to ameliorate the oxidative 
stress, slow the progression or treat the symptoms of these and other 
neurodegenerative disorders, mostly with limited success. The potential reasons 
for the limited success of these compounds are discussed in this thesis, and the 
dissertation research on the potential use of N-acetylcysteine, (NAC) a well- 
known antioxidant and glutathione precursor, is described in detail. 
 
The first portion of the dissertation research described herein focused on 
characterizing the pharmacokinetics of intravenously administered NAC as 
adjunctive therapy with hematopoietic cell transplant (HCT) in ALD.  The 
objectives of this research were to characterize the pharmacokinetics of i.v. NAC 
 and to explore one of the mechanisms by which NAC is thought to exert its 
antioxidant effects: through the provision of cysteine for the synthesis of 
glutathione, the most powerful endogenous antioxidant in the body. 
 
 
The second clinical study described in this thesis focused on the effect of i.v. 
administered NAC on glutathione concentrations measured directly in the brain of 
people with Parkinson’s disease, Gaucher disease and healthy control subjects, 
through the use of magnetic resonance spectroscopy. 
 
 
The research described in this dissertation represents the first report of the 
pharmacokinetics and direct pharmacodynamic effects of i.v. NAC administration 
in those affected by disorders of neurodegeneration.  This research now serves 
as the basis for other pharmacokinetic and pharmacodynamic studies of NAC in 
other populations as well as with other dosage forms and formulations, with the 
hope of developing effective antioxidant treatments for those suffering from 
neurodegenerative disorders. 
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Chapter 1 
Introduction 
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1.1 Oxidative Stress and the Role of Glutathione in Neurodegenerative 
Disorders 
The metabolism of molecular oxygen results in a variety of molecules and free 
radicals (chemical species with one unpaired electron) called reactive oxygen 
species (ROS). Oxidative stress occurs as a consequence of an alteration in the 
equilibrium of the production of ROS and antioxidative processes, in favor of the 
production of ROS. In order to avoid damage caused by ROS, such as lipid 
peroxidation, protein modification, and DNA strand breaks, mechanisms exist 
which remove ROS or prevent the generation of ROS. Although it is not clear 
whether oxidative stress is a precursor or a result of disease processes, it is 
present to some extent in all neurodegenerative disorders. 
 
 
Compared to other organs, the brain has some disadvantages regarding the 
generation and detoxification of ROS. The oxygen requirements of the human 
brain account for 20% of the oxygen consumed by the body, despite the brain 
being only 2% of body weight1 The brain is among the major organs generating 
large amounts of ROS. In cells of the nervous system, the major site of 
physiological ROS generation is the mitochondria. Approximately 2-4% of the 
oxygen consumed by mitochondria is diverted to form superoxide(O2-) 2 
Superoxide dismutase (SOD) converts superoxide to hydrogen peroxide (H2O2), 
which is subsequently converted to water and molecular oxygen by glutathione 
peroxidase (GPx) or catalase.3 Hydrogen peroxide can also react with iron via 
3  
 
 
the Fenton reaction to form hydroxyl radicals, which cause lipid peroxidation.4 
Compared with other organs, the brain is especially vulnerable to oxidative stress 
because it has lower SOD, catalase and GPx activities, while it contains an 
abundance of lipids with unsaturated fatty acids that are targets of lipid 
peroxidation.3 In addition, the brain glutathione(GSH) concentration is lower than 
those of the liver, kidney, spleen or small intestine.5 GSH is a major antioxidant in 
the brain, with a concentration of approximately 2-3 mM; a much higher 
concentration than that in blood or cerebrospinal fluid.6 GSH exerts its action via 
several mechanisms: 
 
 
First, GSH non-enzymatically reacts with superoxide7, nitric oxide (NO) 8 hydroxyl 
radicals9, and peroxynitrite (ONOO-).10 In particular, GSH has a higher ability to 
scavenge superoxide than N-acetylcysteine or cysteine. 11 Furthermore, there is 
no known enzymatic defense against hydroxyl radicals, making GSH the only 
compound capable of scavenging these radicals.9 
 
 
Second, GSH serves as an essential cofactor for a number of enzymes. GSH 
works as an electron donor for the reduction of H2O2 or other peroxides catalyzed 
by GPx.12  H2O2 is reduced to H2O by the reaction of GPx with GSH, which is 
oxidized to GSH disulfide (GSSG).3 GSSG is then reduced back to GSH, a step 
catalyzed by GSH reductase with NADPH, and is then reused as a GPx 
substrate. The relative ratio of the reduced/oxidized forms is over 100 under 
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normal conditions, but is substantially decreased under stressed conditions.13 
This ratio serves as an indicator of the cellular redox environment.14 GSH reacts 
with various endogenous and xenobiotic compounds mediated by glutathione-S- 
transferase (GST) to form mixed disulfides, which are exported to the outside of 
the cell. 
 
 
A third important role of GSH is to serve as a carrier/storage form for cysteine. 
Cysteine itself has neurotoxic effects mediated by free radical generation, 
increasing extracellular glutamate and triggering over-activation of N-methyl-D- 
aspartate (NMDA) receptors.15  GSH is a non-toxic cysteine storage form with 
10-100 times higher concentrations in mammalian tissues than cysteine.16 
 
 
Fourth, GSH is the major redox buffer and maintains intracellular redox 
homeostasis. Under conditions of oxidative stress, GSH can lead to the 
reversible formation of mixed disulphides between protein thiol groups, a process 
critical for preventing irreversible oxidation of proteins.17 
 
 
Fifth, GSH can serve as a neuromodulator/neurotransmitter. GSH binds via its 
gamma-glutamyl moiety to NMDA receptors.18 GSH is thought to exert dual 
(agonist/antagonist) actions on neuronal responses mediated by NMDA 
receptors in the brain.  GSH also serves as an endogenous NO reservoir to form 
S-nitrosoglutathione (GSNO) 19 GSNO can release NO under certain conditions 
5  
with biological effects, while GSNO has a protective effect in brain under 
oxidative stress conditions.20 
 
 
GSH is a tripeptide consisting of glutamate, cysteine and glycine.  The majority of 
GSH in a cell remains in the cytoplasm, where it is synthesized. GSH synthesis 
involves two enzymatic steps which involve ATP. Gamma-glutamylcysteine ligase 
(GCL), also known as γ-glutamylcysteine synthetase, catalyzes the first,         
(and rate-limiting) enzyme-mediated reaction between glutamate and cysteine, to 
form γ-glutamylcysteine, which in turn reacts with glycine catalyzed by GSH 
synthetase(GS) to produce GSH.3  GSH regulates its own synthesis via feedback 
inhibition of GCL.21 Cysteine is the rate-limiting substrate for neuronal GSH 
synthesis. Neurons rely mainly on extracellular cysteine from astrocytes for GSH 
synthesis because they lack the means of direct GSH uptake.22  In the central 
nervous system, astrocytes store high levels of GSH, with concentrations 
reaching as high as 8mM.23 Astrocytes can export their intracellular GSH, 
mediated by gap junction hemichannels, and continuously re-synthesize GSH.24 
In primary neuron culture, approximately 90% of the total cysteine uptake is 
mediated by sodium-dependent systems, mainly the excitatory amino acid 
transporter (EAAT).25 Neurons utilize cysteine but not cystine for GSH synthesis, 
whereas glial cells can utilize both.26 Mitochondria also contain 5-15% of total 
cellular GSH although they cannot synthesize GSH themselves, as they lack 
glutamate-cysteine ligase (GCL) activity.27 
6  
 
 
1.2 X-linked Adrenoleukodystrophy 
 
1.2.1 Pathophysiology 
 
X-linked adrenoleukodystrophy (x-ALD) is a peroxisomal disorder caused by 
mutations in the ABCD1 gene, affecting the function of the encoded protein 
ALDP, an ATP-binding cassette (ABC) transporter located in the peroxisomal 
membrane. There are some 1400+ known mutations identified thus far, with 641 
of them being nonrecurrent mutations.28   ALDP deficiency impairs the 
peroxisomal beta-oxidation of very long-chain fatty acids (VLCFA) and raises 
cytosolic levels of VLCFacyl-CoA.  The VLCFacyl-CoA esters are then further 
elongated by ELOVL, the human C: 26 specific elongase. This increased 
substrate availability caused by the primary deficiency in ALDP appears to 
underlie the enhanced VLCFA elongation and the elevated C:26 plasma levels in 
X-ALD.29 
 
 
The first cases of X-ALD were probably described in the late 19th century. In 
1897 Heubner described a young boy with rapidly progressive neurologic 
deterioration consistent with X-ALD, classified as having “diffuse sclerosis”.30 
Other cases of “diffuse sclerosis” that resemble X-ALD were also described in 
1899 by Ceni and in 1910 by Haberfield and Spieler.31   Shortly thereafter 
Schilder suggested that “diffuse sclerosis” was too vague and proposed a more 
accurate pathological classification of the leukodystrophies. The syndrome of 
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rapidly progressive cerebral demyelination with inflammatory changes in white 
matter on autopsy became known as “Schilder’s disease”.32 
 
 
By the early 1970’s, twelve fully documented clinical reports described boys with 
adrenocortical atrophy and diffuse cerebral sclerosis, along with strong evidence 
of an X-linked recessive mode of inheritance. Forsyth and colleagues 
demonstrated an increase in esterified cholesterol in the white matter and cortex 
of the occipital and parietal lobes of their patients upon autopsy.  Based on this 
finding the authors proposed XALD as an inborn error of metabolism common to 
the adrenal cortex and the brain.33 in 1973, with the use of electron microscopy 
Powers and Schaumburg demonstrated unusual striations in the inner 
adrenocortical cells which were shown to consist of intracytoplasmic lamellae and 
lamellar lipid inclusions. Lipid inclusions were also found in testicular cells, 
Schwann cells and brain microphages from patients with X-ALD.34 Johnson et al 
demonstrated that the striated material from adrenal and cerebral white matter 
was resistant to acetone and ethanol extraction, but readily soluble in nonpolar 
solvents such as hexane and chloroform, suggesting the accumulation of 
unusually nonpolar material in these tissues.35 Subsequently, biochemical 
analysis of the inclusion bodies revealed that they contained cholesterol, 
phospholipids and gangliosides esterified with saturated VLCFA.36  These 
findings defined X-ALD as a lipid-storage disease and led to the hypothesis that 
abnormal metabolism of the VLCFA is a key factor in the pathogenesis of X-ALD. 
Singh and colleagues confirmed this hypothesis by demonstrating that oxidation 
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of C24:0 and C25:0 is reduced in the fibroblasts from X-ALD patients, whereas 
oxidation of radiolabeled C16:0 was fully normal in X-ALD cells.37 In 1984 it was 
demonstrated by Singh that in rat liver and cultured human fibroblasts, 
radiolabeled C24:0 is oxidized mainly and possibly exclusively in peroxisomes 
and that it is this system that is defective in X-ALD. More recently, stable 
isotope-labeled fatty acids have been used to study fatty acid metabolism and 
data have confirmed that beta-oxidation of VLCFAs takes place exclusively in the 
peroxisomes and not in the mitochondria.38 
 
 
The role of VLCFAs in the pathogenesis of X-ALD is largely unknown. VLCFA 
levels in plasma do not correlate with the patient’s phenotype. However, as 
VLCFA accumulation is the only biochemical abnormality that has been identified 
in X-ALD, it seems plausible that this accumulation is somehow related to the 
development of symptoms seen in X-ALD patients.  Further support comes from 
the demonstration of the disruptive effects of C26:0 on cell membrane structure, 
stability and function 39 and the direct toxic effect of C26:0 on adrenocortical cells 
resulting in a decreased response to adrenocorticotropic hormone stimulation.40 
In addition,C26:0 accumulation results in oxidative stress41 and patients with X- 
ALD show evidence of oxidative stress and oxidative damage, particularly in the 
adrenal cortex and brain, from lipid peroxidation.42  A “three hit” hypothesis for  
the pathophysiology of ALD is proposed by Singh et al.  The first hit is the 
metabolic derangements characterized by excess of VLCFA and oxidative stress. 
The second hit is the inflammatory disease that results.  Finally, the inflammatory 
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response further causes a generalized loss of peroxisomes/peroxisomal function 
(third hit), creating a vicious cycle resulting in cell loss and progressive 
inflammatory demyelinating disease.43 
 
 
1.2.2 Epidemiology 
 
X-ALD has an estimated birth incidence of 1 in 16,800 newborns, both male and 
female.44 It is the most common of the peroxisomal disorders and occurs in all 
regions of the world. 45 As newborn screening for X-ALD has now become 
technically feasible, true incidence will be available and may, in reality, be higher. 
 
 
1.2.3 Presentation and clinical course 
 
X-ALD is characterized by the lack of genotype-phenotype correlation. In spite of 
identical ABCD1 gene mutations, patients can exhibit markedly different 
neurologic and neuropathologic characteristics. There is evidence that other 
genetic and/or environmental factors may influence the clinical presentation of X- 
ALD. Segregation analysis suggests that the phenotypic variation is due to at 
least one autosomal modifier gene.46 The symptomatology of X-ALD in children 
and adults is classified in several phenotypes: Addison-only, Cerebral ALD 
(cALD) and Adrenomyeloneuropathy (AMN). 
 
 
Adrenocortical insufficiency or even an Addisonian crisis can be the presenting 
symptom of X-ALD in as high as 35% of all cases, years or even decades before 
the onset of neurological symptoms.47 The recognition of Addison’s disease due 
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to X-ALD has important implications for monitoring and early treatment as well as 
genetic counseling. It is therefore important to consider X-ALD in any boy or adult 
male presenting with Addison’s disease. 
Cerebral ALD in children, adolescence and adulthood are the most rapidly 
progressive and devastating phenotypes of X-ALD. The cerebral form most often 
presents in childhood (childhood cerebral ALD, CCALD), usually between the 
ages of 5 and 12 years, but has not been reported before the age of 2.5 years.48 
CCALD is characterized by progressive cerebral demyelination with a 
pronounced inflammatory response in the white matter leading to 
neurodegeneration and death, often before the patient reaches adolescence. 
Early symptoms include deficits in cognitive abilities that involve visuospatial and 
visuomotor functions or attention and reasoning. The initial symptoms result in 
decline in school performance. These early clinical symptoms are often 
misdiagnosed as attention deficit hyperactivity disorder, and can delay the 
diagnosis of CCALD.  As the disease progresses, more overt neurologic deficits 
become apparent, including withdrawn or hyperactive behavior, apraxia, auditory 
impairment, decreased visual acuity, hemiparesis, cerebellar ataxia and seizures. 
At this stage progression is extremely rapid and devastating. Affected boys can 
lose the ability to understand language and to walk within a few weeks. 
Eventually, patients are bedridden, blind, unable to speak or respond, requiring 
full-time nursing care and feeding by nasogastric or gastrostomy.  Usually death 
occurs two to four years after onset of symptoms, or, if well-cared for, patients 
may remain in this apparent vegetative state for several years.49 Less frequently, 
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cerebral demyelination as the presenting phenotype of X-ALD occurs in 
adolescence (AdolCALD) or adulthood (ACALD).  The symptomatology in these 
patients resembles CCALD, but the initial progression of symptoms is usually 
much slower.  In adults, early cognitive decline is rarely recognized by family or 
coworkers. As the disease progresses, psychiatric disturbances mimicking 
schizophrenia or psychosis are common.50 In these cases, the diagnosis of X- 
ALD is often delayed, particularly when no family history of X-ALD is present and 
when clinical symptoms of Addison’s disease are absent. 
 
 
Approximately 10% of boys or adolescents with cerebral ALD may not develop 
the rapidly progressing neuroinflammatory stage of the disease.  The same may 
occur in men with ACALD or in men with AMN who develop secondary cerebral 
demyelination.  This cerebral demyelinating form of X-ALD is often referred to as 
“chronic or arrested cerebral X-ALD.”  The cerebral demyelinating process 
arrests spontaneously and the patient can remain stable for a decade or even 
longer. But even after a 10-15 year period of stability, sudden onset of rapid 
neurologic deterioration may occur, reflecting a full progression to the 
neuroinflammatory stage of the disease.31 
 
 
Virtually all patients with X-ALD who reach adulthood will develop AMN, usually 
in the third or fourth decade. Patients develop gradually progressive spastic 
paraparesis, sensory ataxia with impaired vibration sense, sphincter dysfunction, 
pain in the legs and impotence.51 The pathological basis of AMN is a 
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noninflammatory distal axonopathy that involves the long tracts of the spinal cord, 
and to a lesser extent, the peripheral nerves. This phenotype is most often slowly 
progressing, causing severe motor disability of the lower limbs over one to       
two decades but mild or no significant deficits in the upper limbs or hands.31 
Approximately 20% of AMN patients develop cerebral demyelination, according 
to a 10-year retrospective study.52 After an initial progression, the demyelinating 
lesions can stabilize spontaneously, leading to moderate cognitive deficits. 
However, once the cerebral demyelinating lesions have entered the active phase 
of neuroinflammation, the prognosis is as poor as in CCALD.53 
 
 
Unlike many x-linked diseases where female carriers remain asymptomatic, 
many women with X-ALD develop AMN-like symptoms. The onset of neurologic 
symptoms occurs mainly between the fourth and fifth decade and they are very 
similar to those observed in adult males with AMN.  Sensory ataxia, fecal 
incontinence and pain in the legs are more prominent in symptomatic women 
with AMN. Cerebral involvement and adrenocortical insufficiency are rare, 2% 
and 1% respectively.49 
 
 
X-ALD phenotypes are not static.  Presymptomatic males are nearly all at risk to 
develop neurologic disease (cALD or AMN), or endocrinologic symptoms 
(Addison’s disease).  Addison-only males can develop AMN or cerebral ALD, and 
AMN males can develop cerebral demyelination.  Presymptomatic women with 
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X-ALD are at risk to develop AMN.  Progression of X-ALD in a specific individual 
cannot be predicted. 
 
 
1.2.4 Diagnosis and Management of X-ALD 
 
Newborn screening based on the measurement of C26:0 lysophosphatidyl- 
choline (26:0-lyso-PC) in dried blood spots 54 is now technically feasible, but is 
not widely used.  This screening could lead to identification of pre-symptomatic 
patients with X-ALD, but its implementation is a matter of public policy and ethical 
considerations are still being discussed. 
 
 
If X-ALD is suspected in a male with neurological symptoms or Addison’s 
disease, VLCFA elevation in plasma is the first step in making the diagnosis. 
Since increased plasma VLCFA are not pathognomonic for X-ALD, if metabolic 
screening reveals increased VLCFA, the next step is to confirm the diagnosis by 
performing ABCD1 mutation analysis. For women with X-ALD, the diagnostic test 
of choice is mutation analysis, as about 15% of women with X-ALD have normal 
plasma VLCFA levels.55 Family screening should be done by mutation analysis 
as well. 
 
 
Boys or men who do not have Addison’s disease should be evaluated yearly by 
an endocrinologist for adrenocortical dysfunction. Steroid (ACTH) replacement 
can be initiated if necessary. 
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Boys aged 3-12 years old without neurological deficits should be monitored every 
6 months with magnetic resonance imaging (MRI) for signs of cerebral ALD. 
About 80% of boys with cALD display the posterior pattern of demyelination on 
MRI. The lesion starts in the splenium of the corpus callosum and spreads out 
into the parieto-occipital white matter. In approximately 10-20% of boys with 
inflammatory cerebral involvement, the process is reversed and starts in the 
frontal regions with concomitant involvement of the rostrum and genu of the 
corpus callosum.55   The 34-point severity score has been developed by Loes et 
al. for use in monitoring location, extent of involvement and presence of focal 
and/or global atrophy with each 6 month MRI.56 High-field magnetic resonance 
spectroscopy (MRS) studies have shown that abnormal reductions in N- 
acetyaspartate:choline ratio precedes the development of changes on MRI.57 
These changes could prove useful in determining when to move to treatment with 
limited available therapies for cALD. 
 
 
Allogeneic hematopoietic stem cell transplantation (HCT), despite its significant 
mortality risk, is the only known therapeutic intervention which can arrest the 
progression of cerebral demyelination in X-ALD.58 If performed early, when 
affected males have no or minor symptoms due to the cerebral demyelinating 
disease, HCT demonstrates excellent likelihood of survival with good neurologic 
and neuropsychological function in most boys. However, once pronounced 
cerebral involvement exists along with neurological deficits, HCT is often not 
successful in prolonging survival or preserving function.59 Based on evidence that 
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oxidative stress and oxidative damage contribute to the central nervous system 
damage seen in X-ALD, Tolar et al demonstrated improved survival using adjuct 
N-acetylcysteine (NAC) therapy in boys undergoing HCT for advanced cerebral 
X-ALD.60 This work will be discussed in a later chapter. Recently, transplantation 
with autologous bone marrow transfected in vitro with ABCD1 has been 
performed with success. So far, bone marrow transplant has only been reported 
in children with cerebral ALD. There is little reason why it should not be equally 
effective in adults. Preliminary experiences from transplant centers in Germany 
and France show survival rates comparable to those in childhood cerebral ALD; 
however, pre-existing severe AMN symptoms such as motor disability or urinary 
incontinence seriously influence the clinical outcome after transplantation.61 
 
 
For adult men with or without signs of AMN, yearly evaluation by a neurologist is 
recommended.  Since adult men can develop cerebral ALD, an MRI is usually 
performed.  There is no proven treatment for cerebral ALD in adults, but studies 
of HCT have included very small numbers of adult men. For AMN there is no 
effective disease modifying therapy available yet. Lorenzo’s Oil (LO), a mixture 
of glycerol trioleate and glycerol trierucate oils, showed great promise, but open- 
label trails have shown that the disease progresses even when plasma VLCFA 
are normalized by LO treatment.62, 63 A large randomized placebo-controlled 
clinical trial was designed to provide a definitive answer, but was unfortunately 
aborted before completion by the safety monitoring board because of presumed 
side effects of the placebo treatment. There is also a retrospective study 
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suggesting that if presymptomatic boys are started on LO, it may delay the onset 
of neurological symptoms.64 Currently, Lorenzo’s oil is available through 
expanded access to males with x-linked adrenoleukodystrophy, as determined by 
biochemical or genetic determination, between the ages of 18 months to 18 years 
who have a normal cerebral MRI at baseline.65 
 
 
Lovastatin also lowered plasma VLCFA 66, but a placebo-controlled trial revealed 
that lovastatin did not have an effect on the C26:0 level in peripheral blood 
lymphocytes and erythrocytes nor on the VLCFA content of low-density 
lipoprotein fraction.65  Antioxidants reduce markers of oxidative stress and axonal 
degeneration in the spinal cord of Abcd1 knockout mice.67   Based on this 
observation, a clinical trial with anti-oxidants in AMN is ongoing in Spain.68 
Bezafibrate has been shown to decrease VLCFA in X-ALD fibroblasts by direct 
inhibition of fatty acid elongation activity.69  A proof of principal trial showed that 
bezafibrate was unable, at least in the doses given, to lower VLCFA levels in 
plasma or lymphocytes in patients with X-ALD.70 
 
 
1.3 Parkinson’s disease 
 
1.3.1 Pathophysiology 
 
Parkinson’s disease (PD) is typically a late-onset neurodegenerative disorder 
characterized by difficulty initiating movement, rigidity, tremor and postural 
instability. While motor dysfunctions represent the most often seen clinical 
features of the disease, non-motor symptoms such as sleep disturbances, 
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dementia and depression often also occur. Motor disturbances are produced 
predominantly by the degeneration of dopaminergic neurons of the substantia 
nigra and their projections to the striatum, although other neuronal populations 
are affected in the disease. 
 
 
In recent years, strides have been made in understanding the initiating causes of 
familial PD. Genetic mutations in several genes including α-synuclein, Parkin, 
UCH-LI, DJ-1, PINK-1 and LRRK2 have been identified, providing hope for 
potential therapeutic interventions.72,73   Alpha-synuclein is the major protein 
component of Lewy bodies, the pathological hallmark not only in the brains of 
mutation carriers, but also in the common sporadic for of PD. Genome-wide 
association studies have revealed that genetic variants in the α-synuclein gene 
represent the most consistent risk factor for PD across different populations. 
Familial PD, however, accounts for only 5-10% of the all Parkinson disease. 
Although genetics have not revealed an underlying cause for sporadic or 
idiopathic PD, growing evidence implicates other biochemical abnormalities 
including: oxidative stress, mitochondrial dysfunction, proteasomal dysfunction 
and GSH depletion. Oxidative stress can induce mitochondrial DNA mutations, 
damage the mitochondrial respiratory chain, alter membrane permeability and 
influence calcium ion homeostasis and mitochondrial defense systems. Once 
damaged, mitochondrial DNA can amplify oxidative stress by decreased 
expression of critical proteins important for electron transport, leading to a vicious 
cycle of ROS and organelle dysregulation that eventually triggers apoptosis.74 
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Dysfunction of molecular and organelle degradation pathways is a further 
hallmark of PD and increasing evidence indicates functional interactions between 
the ubiquitin proteasome system and autophagy.75,76 While both degradation 
systems are involved in the clearance of misfolded proteins, a special form of 
autophagy also known as mitophagy removes defective mitochondria from 
cells.77 This clearance process is controlled via PINK1 and Parkin.78 In PD, the 
dysfunction of these clearance systems facilitates the accumulation of α- 
synuclein and defective mitochondria.  A positive feedback loop, which turns 
seemingly mild dysfunctions in misfolded protein handling into a self-perpetuating 
cycle, is indicated by the finding that mutated forms of α-synuclein may inhibit 
their own degradation via chaperone-mediated autophagy.79 Although the cause 
or consequence of each of these in relation to PD is unclear, most evidence 
points to GSH depletion as an early forerunner to the cascade of events leading 
to the loss of dopaminergic neurons. 
 
 
1.3.2 Epidemiology 
 
Parkinson’s disease is the second most common neurodegenerative disease 
worldwide, affecting 0.3% of the general population, and 1% of the population 
older than 60 years. At the age of 80, the prevalence rises to 3%.80  Mean age of 
onset is 65 years, with those diagnosed early in adulthood typically having slower 
disease progression than those diagnosed later in life.81 The ratio of men to 
women affected is 1.5:1.82  Idiopathic Parkinson disease is much more common 
than hereditary PD, occurring in about a 90:10% ratio.83 PD protective factors 
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include cigarette smoking and high coffee consumption. Risk factors include a 
family history of PD, pesticide exposure and head injury.  Constipation was 
thought to be a risk factor for PD, but is now thought to be an early symptom of 
the disease.84 To date, aging represents the most significant risk factor for 
developing PD.85 
 
 
1.3.3 Presentation and Clinical Course 
 
The clinical syndrome of idiopathic PD is characterized by bradykinesia, resting 
tremor, rigidity and postural instability. In addition to these motor symptoms, 
many patients experience a wide range of non-motor symptoms that sometimes 
even precede the typical movement disorder, such as hyposmia, sleep 
disturbances such as REM sleep behavior disorder, fatigue, depression, 
constipation and other dysautononmic symptoms.86 
The course of PD varies widely, but appears to occur in three major clinical 
subgroups: tremor dominant (8%), akinetic-rigid (26%) and mixed, which is the 
most prevalent (66%).87 Late symptoms, occurring by approximately 15 years 
after symptom onset, include freezing, postural instability, falls and dysphagia. 
Psychiatric and autonomic disturbances typically occur 5-10 years after symptom 
onset and include anxiety, postural lightheadedness, sialorrhea, urinary urgency, 
nocturia, and sexual dysfunction. The likelihood of cognitive impairment 
increases with time after symptom onset. Approximately 35 % of patients 
experience mild cognitive impairment at diagnosis and 50% after 5 years from 
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diagnosis. Approximately 80% or greater will experience dementia 20 years after 
diagnosis. 88-92 
 
 
1.3.4 Parkinson disease management 
 
There are no established disease-modifying or neuroprotective therapies for PD. 
Medications for symptom management are usually initiated when patients 
experience functional impairment or social embarrassment from their symptoms. 
If motor symptoms are mild but require therapy, a monoamine oxidase type B 
inhibitor (MAOBI; selegiline or rasagiline) may be tried before moving to more 
potent treatment such as a dopamine agonist or levodopa. A disease-modifying 
effect of rasagiline has been reported, but has not been confirmed by other 
clinical trials.93 Anticholinergic medications have been shown to be effective for 
improving motor function in PD, but data on their benefits for tremor were 
inconclusive.94 Older studies suggest that β-blockers such as propanolol may 
improve parkinsonian tremor and motor function.95 Clozapine has been shown to 
improve Parkinson disease tremor, but is generally reserved for bothersome or 
disabling tremor resistant to other therapies.96 Evidence supporting amantadine 
for treatment of Parkinson’s disease is mixed, however expert opinion from the 
International Parkinson and Movement Disorder Society and European 
Federation of Neurological Societies concluded that amantadine is likely 
efficacious for symptomatic monotherapy and adjunct therapy. For those with 
more severely impaired activities of daily living, levodopa or a dopamine agonist 
is usually initiated.  Multiple large clinical trials demonstrate that levodopa 
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provides the greatest symptomatic benefit for Parkinson disease and is 
associated with less freezing, somnolence, edema, hallucinations and risk of 
impulse control disorders than dopamine agonists.97 Dopamine agonists are also 
effective in early Parkinson disease and are less likely than levodopa to cause 
dopaminergic motor complications, particularly dyskinesia. Because younger 
age-at-onset of Parkinson disease is a risk factor for dyskinesia, dopamine 
agonists are usually introduced as initial treatment for patient younger than 60 
years.98 
 
 
Managing motor fluctuations, including symptom reemergence between 
medication doses can be difficult in some patients with Parkinson disease. 
Strategies for reducing the time that medication is not optimally effective (“off” 
time) include increasing the dosage of dopaminergic medication, adding another 
dopaminergic medication, dividing the  levodopa dosage into smaller but more 
frequent doses (levodopa dose fractionation), or adding a catechol-O- 
methyltransferase inhibitor (COMTI) or MAOBI to inhibit the breakdown of 
levodopa and dopamine and prolong their effects.99  There is extensive but 
conflicting evidence for the use of selegiline to reduce off time.100,101 Dopamine 
agonists may be added to levodopa to reduce off time. Adjunctive pramipexole, 
ropinirole and transdermal rotigotine have all shown a significant reduction in off 
time compared with placebo in well controlled studies. Intermittent, as needed, 
subcutaneous apomorphine provides rapid delivery to reduce bothersome off 
periods, but may increase dyskinesia.102  A study of levodopa-carbidopa intestinal 
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gel, administered directly into the duodenum by pump through a gastrostomy 
catheter, confirmed earlier small, open-label studies showing a marked reduction 
in off time.103 
 
 
Treatment of severe or bothersome dyskinesia may involve dopaminergic 
medication reduction, but this will typically often worsen parkinsonism. 
Amantadine is frequently used for reducing dyskinesia severity and duration, and 
is typically well tolerated.104 Levodopa-carbidopa intestinal gel may be useful in 
the future and exploratory trials of other agents are ongoing. 
 
 
Other medication adverse effects such as nausea, psychosis, impulse control 
disorders, dopamine dysregulation syndrome and punding all pose additional 
challenges in the treatment of PD. Nausea is a frequent, generally transient 
adverse effect of dopaminergic therapy. Slow titration of dopaminergic therapy 
and medication administration with food can reduce nausea; however, food may 
delay gastric emptying and dietary protein may interfere with levodopa 
absorption.  An additional dose of carbidopa (which inhibits peripheral conversion 
of levodopa to dopamine) 30 minutes before dosing levodopa, may prevent 
levodopa-induced nausea, but not dopamine-agonist-induced nausea. 105 
Medications such as domperidone, a peripheral dopamine D2-receptor agonist 
may reduce nausea from dopaminergic medications, but is still unavailable in the 
U.S.106  Impulse control disorders (ICDs)are typically, but not entirely, associated 
with dopamine agonist use.107 A history of obsessive-compulsive disorder, 
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impulsive personality, or addictive behaviors increases the likelihood of ICDs. 
Dopamine agonist dose reduction or discontinuation, offset by increasing 
levodopa, in generally effective treatment in ICDs. Withdrawal symptoms may 
include anxiety, depression, fatigue, pain, orthostatic hypotension, and drug 
cravings (dopamine agonist withdrawal syndrome), and may be unresponsive to 
increasing levodopa in 15-20% of patients.108 Management of dopamine 
dysregulation syndrome (DDS) typically involves a gradual reduction of levodopa 
and immediate discontinuation of “booster” doses of medications such as 
subcutaneous apomorphine boluses or rapid-acting levodopa formulations.109 No 
studies have formally examined the management of DDS, but a small case series 
of 4 PD patients reported a response to valproate in all 4 patients.110            
Punding, defined as repetitive, often purposeless, stereotyped behaviors such as 
sorting or disassembling, occur in up to 15 % of Parkinson patients. Management 
of this adverse effect may include reduction or cessation of dopaminergic 
medications. A small open-label study indicated that amantadine and quetiapine 
may also be beneficial. 111 
 
 
Hallucinations are both a feature of later-stage Parkinson disease and a 
consequence of Parkinson disease medications. Additional psychotic symptoms 
however, are generally thought to be drug-related.  Clozapine and quetiapine 
have been most extensively studied for the treatment of psychosis in Parkinson 
disease, since other neuroleptics have the propensity to worsen parkinsonism. 
Clozapine is consistently efficacious in a number of studies, whereas the results 
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for quetiapine as mixed.112,113  Quetiapine is prescribed first most often because 
of the risk of agranulocytosis and the requirement for frequent blood monitoring 
with clozapine.  Treatment approaches to new-onset or increased hallucinations 
include initial exclusion of systemic illness, such as infection or other medication 
use. Subsequent reduction or discontinuation of antiparkinsonian drugs is done in 
order from lowest efficacy, starting with anticholinergics, amantadine, and 
MAOBIs, followed by dopamine agonists and COMTIs114 Finally, the levodopa 
dose is cautiously reduced and the patient is monitored for a disabling increase  
in parkinsonism, including the rare occurrence of neuroleptic malignant like state. 
Again, clozapine clearly has the highest efficacy for hallucinations and psychosis. 
A recent study showing efficacy for the selective 5-HT2A inverse agonist 
pimavanserin for psychotic symptoms provides new hope for therapies that do 
not require extensive monitoring.115 
 
 
The management of non-motor symptoms is another challenge in the treatment 
of Parkinson disease. Rapid eye movement sleep behavior disorder, depression 
and cognitive impairment are a few of these troublesome effects of PD. 
Clonazepam is a first-line therapy for rapid eye movement sleep behavior 
disorders (RBD) in general, but only a few case reports and case series are 
reported on its use in PD patients. There is similarly little evidence for the use of 
melatonin in RBD specifically in PD, but it may be an alternative to clonazepam 
for those patients in whom clonazepam is contraindicated such as those with 
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dementia, obstructive sleep apnea, or extreme frailty with an increased risk of 
falls.116 
 
 
The literature on the management of depression in PD is mixed. A 2013 
systematic review found no statistically significant superiority of antidepressants 
compared with placebo, as a group or by class, but tricyclic antidepressants were 
superior to selective serotonin reuptake inhibitors.117 Tricyclic antidepressants 
were found to be superior to placebo in other studies, but their use may be limited 
due to concerns about the adverse effects in older patients who are cognitively 
impaired.118 
 
 
PD management represents a considerable challenge to the medical community, 
and more importantly to those who suffer from its effects. Given the progressive 
nature of this disease, and its multifaceted disability, the greatest unmet 
therapeutic need is the identification of effective neuroprotective and disease 
modifying therapies. 
 
 
1.4 Gaucher disease 
 
1.4.1 Pathophysiology 
 
Gaucher disease (GD), the most common autosomal recessive lysosomal 
storage disease, is caused by a deficiency or absence of the activity of the 
enzyme glucocerebrosidase, which breaks down the glycolipid glucocerebroside 
into glucose and ceramide inside the lysosome.  Glucocerebrosidase is encoded 
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by the glucocerebrosidase (GBA1) gene. Mutations in the GBA1 cause 
glucocerebrosidase deficiency and the subsequent accumulation of the 
undegraded substrate glucocerebroside inside the lysosome of cells composing 
the reticulo-endothelial system. This accumulation results in Gaucher disease.118 
The main biological function of macrophages is phagocytosis-mediated 
breakdown of aging cells such as erythrocytes, which have glucocerebroside-rich 
membranes. Gaucher disease macrophages that have accumulated 
glucocerebroside appear engorged and are often referred to as “Gaucher cells”. 
Gaucher cells primarily populate the spleen, liver and bone marrow, resulting in 
inflammation and organomegaly.119 
 
 
1.4.2. Epidemiology 
 
Gaucher disease affects men and women equally.  According to a report by the 
National Organization for Rare Disorders, the GD incidence rate may be as high 
as 1 in 450 births among individuals with Ashkenazi Jewish ancestry and 
1:20,000 to 1:200,000 in the general population.120 The National Gaucher 
Foundation estimates the incidence of GD type 1 (GD1) in the U. S. to be about 1 
in 20,000 live births or a prevalence of about 1 in 40,000. 121 A high prevalence of 
GD1, especially with mutations N370S and 84GG, is seen among Ashkenazi 
Jews, whereas mutations in N370S are found among North American, European 
and Israeli populations. GD1 occurs mainly in adults and is the most frequent 
type, accounting for 95% of GD cases. GD type 2 (GD2) is rare, occurring in 
fewer than 1 in 100,000 people and generally affects infants 4-5 months old.122 
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GD type 3 (GD3) is also a rare form that affects fewer than 1 in 100,000 
people.123 
 
 
1.4.2 Presentations and Clinical Course 
 
GD is classified into GD1 (non-neuropathic), GD2 (acute neuropathic), and GD3 
(chronic neuropathic), according to the presence of neurological deterioration, 
age at identification and disease progression rate. If GD onset occurs prior to 
adulthood, a more rapidly progressing disease is suspected.  GD1 is associated 
with visceral complications without CNS involvement. However, the wide 
spectrum of clinical manifestations seen in patients with type 1 GD has led many 
to argue that this classification system is too simplistic. Indeed the observation of 
parkinsonism, dementia and subclinical peripheral neuropathy in patients with 
type 1 GD has challenged the more traditional definition as non-neuronopathic. 
Initial manifestations normally begin with splenomegaly, hepatomegaly, anemia, 
leukopenia and thrombocytopenia.124  Further progression involves 
gastrointestinal complications such as portal hypertension, cirrhosis, ascites, 
esophageal hemorrhage, and bone lesions manifested in chronic bone pain, 
skeletal deformities, osteonecrosis, osteopenia, and osteoarticular infections.125. 
GD2 and GD3 are neuronopathic variants with several distinguishing 
characteristics. GD2 involves the brain, spleen, liver, and lungs, with severe 
neurological complications.  The disease progresses rapidly, leading to death 
within the first 2 years of life.126 GD3 has only mild visceral manifestations but 
causes severe, progressive myoclonic seizures, which can lead to death within 
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the first 2 decades. GD3b involves more visceral features, such as massive 
hepatosplenomegaly, growth retardation and supranuclear gaze palsy.127 GD3c 
patients with a specific genetic mutation (D408H) will often die in early adulthood 
due to a rare cardiac mitral and aortic calcification.128 
 
 
GD1 is classified according to clinical severity scores using a scoring system: 
Gaucher Disease Severity Score Index, Type 1 (GauSSI-1). This severity score 
allows for a more thorough and reliable method to correlate the differences in 
genotypes and phenotypes of the patients, to correlate patient response to 
biological markers and to account for the variability in clinical response and 
severity of disease. There are six domains to score in the GauSSI-1: skeletal, 
hematological, biomarker, visceral, lung, and neurological.  The severity of 
symptoms or other objective measures are scored with a possible 42 points with 
higher scores reflecting more severe GD. 129 
 
 
Among the neurological complications of GD1 is parkinsonism.  This has 
challenged the traditional classification of type 1 GD as non-neuronopathic, as 
mentioned earlier.  The possibility of a link between the two diseases was first 
suggested in the clinic setting where a small number of case reports described 
parkinsonism features in GD patients.130   Larger studies have since been 
published which have confirmed these findings.131   Heterozygote carriers of 
mutations in the BGA gene also have an increased frequency of Parkinson 
disease, and approximately 5-10% of PD patients have GBA mutations, 
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confirming mutations of this gene as numerically the most important genetic 
predisposing risk factor for PD identified to date.132 Data on the penetrance and 
lifetime relative risk (RR) of PD in patients with GD are conflicting.  Some studies 
report a slightly higher estimated penetrance and lifetime RR of PD in 
heterozygous GBA mutation carriers compared to GD patients, but this may 
reflect differences in size of the cohorts evaluated, rather than a significant 
difference in the overall risk of PD between the two groups.  Studies have 
investigated the frequency of GBA mutations in patients with sporadic PD and 
have shown that the odds ratio for a known patient with idiopathic PD to harbor 
one GBA mutation is 5.4.133 Additionally, when compared to other PD-related 
genes such as α-synuclein and parkin, the frequency of GBA mutations is higher 
in individuals with parkinsonism.134  Of further interest is a recent study that 
identified a GBA mutation (E326K) that can predispose to PD but is a variant that 
does not, when homozygous, cause PD.135 
 
 
To date, over 300 GBA1 mutations and polymorphisms have been reported, but 
correlations between the clinical phenotype and molecular genotype remain 
limited.  Studies have shown that patients with identical genotypes can have 
vastly different clinical manifestations and severity, even between siblings and 
twins, whereas patients with different molecular genotypes can share similar 
clinical phenotypes. 136 Furthermore, there is not a strong correlation between the 
amount of accumulated substrate and/or residual glucocerebrosidase enzyme 
activity and clinical manifestations in patients.  This suggests that Gaucher 
30  
disease is not a “simple” monogenic disorder, and that additional factors such as 
epigenetics and/or genetic modifiers may contribute to disease development and 
phenotype.137 
 
 
1.4.3 Diagnosis and Management of Gaucher disease 
 
GD is often diagnosed during initial clinical examination by the presence of 
unexpected anemia, thrombocytopenia and organomegaly. Clinical diagnosis is 
confirmed by biochemical diagnosis. Detection of low enzymatic activity of GBA 
in the peripheral blood compared with normal control is still the gold standard for 
diagnosing GD.138 
 
 
Therapeutic treatment options in GD consist of enzyme replacement therapies 
(ERT) and substrate reduction therapy (SRT). The first ERT was introduced in 
1991.  The placental-derived macrophage-targeted glucocerebrosidase, 
alglucerase (Ceredase, Genzyme Corp.) led to the revolution in GD management 
and this finding also led to the use of ERT for other lysosomal storage disorders. 
In 1994 imiglucerase (Cerezyme, Genzyme Corp.) was approved by the FDA. 
Imiglucerase is an analog of glucocerebrosidase produced by DNA technology 
using Chinese hamster ovary cells, and subsequently replaced alglucerase.  In 
June of 2009, Genzyme Corporation announced a viral contamination at its 
manufacturing site, and the dramatic reduction in available supply to 20% left the 
ERT unavailable to many patients worldwide.  This shortage of ERT stimulated 
interest in the development of 2 new ERTs. 
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In 2010, velaglucerase alfa (VPRIV, Shire Human Genetics therapies, Inc), an 
analogue of recombinant glucocerebrosidase produced in human fibroblast cell 
lines, became the third ERT approved by the FDA.139 In May 2012, FDA 
approved taliglucerase alfa (ELEYSO, Pfizer Inc.), which is produced genetically 
by modified carrot cells. The availability of a plant-cell-derived system to 
manufacture taliglucerase alfa offers the possibility of large-scale production of 
the enzyme at a lower cost and lowered potential for shortages. All three ERTs 
currently available are administered every other week via intravenous injection. 
Common hypersensitivity reactions and production of antibodies may occur with 
all available ERTs. All are incapable of crossing the blood-brain barrier and are 
specifically indicated for moderate to severe GD1 treatment.140 
 
 
In contrast to ERT, which aims to replace the defective enzyme with active 
enzyme, SRT targets the biosynthetic pathway and reduces the load of 
glucocerebroside influx into the lysosome. Miglustat (Zavesca, Actelion 
Pharmaceuticals Limited) is a synthetic D-glucose analogue which works by 
inhibiting the enzyme glucocerebrosidase, the enzyme responsible for 
glucocerebroside synthesis and other glycosphingolipids, thus reducing it to 
residual activity and preventing its influx into the lysosome.  The drug was FDA 
approved in 2003 for the treatment of mild to moderate GD3, and is orally 
administered three times daily.  Since Miglustat is capable of penetrating the 
blood-brain barrier, it was intended as a prototype for the management of the 
neuronopathic forms of GD. Although this SRT offers more convenient dosing 
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than available ERTs, clinical trials with miglustat in GD3 patients showed no 
improvement in neurological symptoms. The drug also caused a higher incidence 
of adverse reactions such as tremor, weight loss, reduced platelet counts, 
numbness and feeling of burning on the hands and feet. Moreover, long-term 
reductions of glycosphinglolipids could affect a variety of cellular functions 
because of the essential roles of these lipids.141 Miglustat is now approved in the 
U.S. for patients who cannot take ERT because of anaphylactic reactions. 
Another SRT, eliglustat (Cerdelga, Genzyme Corp.) was just recently FDA 
approved for select GD1 patients. This drug is predominantly metabolized by 
CYP2D6, and metabolizer status must be taken into consideration when dosing 
this therapy. The FDA indication is for the long-term treatment of adult patients 
with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers 
(EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected 
by an FDA-cleared test.142 Because eliglustat does not penetrate the blood-brain 
barrier, it may not add value in the treatment of neurologic symptoms of GD. 
 
 
In addition to ERT and SRT, other supportive management strategies are 
necessary to alleviate the disease symptoms such as bone disease, 
hepatosplenomegaly, bleeding, pulmonary hypertension, seizures, and 
parkinsonism. Treatment of bone disease with bisphosphonates is usually 
necessary.  In severe thrombocytopenia or symptomatic organomegaly 
unresponsive to ERT, splenectomy might be necessary. Defects in platelets, 
coagulation and non-corrected thrombocytopenia pathways may cause increased 
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bleeding risk in GD patients and require constant monitoring.143  In patients with 
moderate to severe GD with life-threatening complications such as 
hepatopulmonary syndrome and pulmonary hypertension, higher doses and 
longer treatment with ERT may be needed along with adjuvant therapy such as 
vasodilators and/or warfarin.  For visceral and neurologic complications, the best 
option currently is higher doses of ERT. For those GD patients who develop 
Parkinson disease, improvements and worsening of symptoms may occur 
despite optimized ERT therapy.144  Because of the severity and complexity of 
GD, healthcare providers need to individualize treatment options, as limited 
standardized treatment guidelines are available. 
 
 
In recent years a few studies have shown promising results using gene therapy 
and chaperone treatment in animals. Studies using murine GD1 models injected 
with lentiviral and null mice GD models injected with adeno-associated viral 
vector harboring the human GBA1 gene have shown promising results. 145,146 
These vectors induce the liver to secrete GBA1 in young animals and older mice 
with GD. Abnormal protein folding is thought to be a mechanism in many 
inherited diseases, and chaperone therapy is based on the ability of small 
molecules to interact with mutant proteins that are misfolded. Chaperone 
molecules bind to GBA1 during biosynthesis, then dissociate from the enzyme for 
delivery to the lysosome, allowing BGA1 to be delivered to the normal site. So 
far, studies of chaperone therapies in GD have shown disappointing results, but 
may be an option for combination treatment strategies in the future. 147 
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CHAPTER 2 
 
ANTIOXIDANTS IN NEURODEGENERATIVE DISORDERS 
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2.1 Select antioxidants previously studied in neurodegenerative disorders 
 
2.1.1 Vitamin E 
 
 
The nervous system is vulnerable to the damaging effects of highly reactive free 
radicals for several reasons. The brain contains high amounts of 
polyunsaturated fatty acids that are susceptible to lipid peroxidation, receives a 
large percentage of oxygen, and is relatively deficient in certain antioxidant 
enzymes.  In addition, specific regions of the brain have high iron concentrations. 
Thus, antioxidant defenses are critically important to protect the brain and neural 
tissues from oxidative damage. Neuroprotection by antioxidants such as vitamin 
E has therefore drawn much interest.  Vitamin E is the major lipid-soluble, chain- 
breaking antioxidant in the body, protecting the integrity of membranes by 
inhibiting lipid peroxidation.  Mostly on the basis of symptoms of primary vitamin 
E deficiency, including peripheral neuropathy, it has been demonstrated that 
vitamin E has a central role in maintaining neurologic structure and function.148 
Since orally supplemented vitamin E reaches the cerebrospinal fluid and brain, it 
has been extensively studied for its antioxidant effects.149 Several animal studies 
have shown vitamin E to be neuroprotective against free radical-mediated injury, 
protect neurons of the locus coeruleus from death in an early model of PD,150 
prevent the toxin-induced destruction of striatal dopaminergic terminals,151 and 
regulate the levels of antioxidant defenses such as glutathione and superoxide 
dismutase.152 These preclinical studies prompted a large, multicenter study of 
vitamin E in slowing the progression of PD. 
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In 1987, the DATATOP (Deprenyl And Tocopherol Antioxidative Therapy Of 
Parkinsonism) clinical trial was initiated under the primary sponsorship of the 
National Institute of Neurological Disorders and Stroke (NINDS) of the National 
Institutes of Health. Deprenyl (selegiline), a type-B monoamine oxidase 
inhibitor, and a-tocopherol, the biologically active antioxidant of vitamin E, were 
hypothesized to slow the clinical decline in patients with early and otherwise 
untreated PD. The DATATOP trial was based on the assumption that deprenyl or 
tocopherol, alone or in combination, would slow disability over a 2-year period of 
observation. DATATOP was designed as a 2 X 2 factorial, double-blinded, 
placebo-controlled multicenter trial to determine if deprenyl 10 mg/day and/or 
tocopherol 2,000 IU/day, administered to otherwise untreated patients with early 
PD, would prolong the time until levodopa therapy was judged necessary to treat 
emerging disability.  Between September 1987 and November 1988, 35 
Parkinson Study Group (PSG) investigators enrolled 800 patients with early, 
untreated PD from 23 research sites in the United States and five in Canada. 
After baseline evaluation and randomization to one of four treatment  
assignments (double-placebo, active deprenyl alone, active tocopherol alone, 
both active deprenyl and tocopherol), subjects were re-evaluated at 1 and 3 
months and then at approximately 3-month intervals with respect to standardized 
clinical measures, including the Unified Parkinson Disease Rating Scale 
(UPDRS). The primary endpoint of the study was functional disability sufficient to 
warrant the initiation of levodopa therapy. 153 On the basis of follow-up of the 
initial 14 ± 6 (mean ± SD) months of the DATATOP trial, the beneficial effects of 
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deprenyl were confirmed and occurred largely during the first 12 months of 
treatment and significantly delayed the onset of disability that would require 
levodopa therapy (hazard ratio 0.50; 95% CI, 0.41-0.62; p < 0.001). The 
difference in the estimated mean time to the end point of disability was about 9 
months, when subjects assigned to deprenyl were compared with those not 
assigned to deprenyl. The study found no beneficial effect of tocopherol and no 
interaction between tocopherol and deprenyl. 
Despite these results, vitamin E has been studied in conjunction with other 
antioxidants in PD, including vitamin C and more recently, coenzyme Q10, which 
will be discussed in subsequent sections of this chapter. 
 
 
2.1.2 Vitamin C 
 
Vitamin C (ascorbic acid) is a required nutrient for a variety of biological  
functions. Humans and other primates have lost the ability to synthesize ascorbic 
acid due to a defect in L-gulono-1, 4-lactone oxidase, an enzyme that     
catalyzes the conversion of L-gulonolactone into ascorbic acid.154 Humans, 
primates and a few other animals depend on the diet as a source of vitamin C to 
prevent disease and maintain general health. For many years it was widely 
believed that the only function of ascorbate or vitamin C in the body was to 
promote collagen synthesis and that its only role in therapeutics was to treat 
scurvy. In the late 1990’s, it became evident that ascorbate had important 
functions in the body, particularly in the brain.155 Ascorbate concentrations in the 
CSF of about 200µM have been reported, in contrast to plasma concentrations of 
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50 µM or less. It appears that much of the ascorbate in brain is in the neurons 
themselves. High ascorbate concentrations have been localized in the neuron- 
rich areas of  the hippocampus and neocortex in human brain, where the 
ascorbate content in as much as two-fold higher than in other brain regions.156 
The major route by which ascorbate enters the CNS involves transport from 
plasma to the CSF across the epithelium of the choroid plexus.157   Two  
ascorbate transporters, first cloned in 1999, are known thus far: sodium- 
dependent vitamin C transporter type 1 (SVCT1), which resides primarily in the 
brush-border membranes of intestinal and renal tubular cells, and SVCT2, which 
is found in most other tissues, including the brain.158  Once in the CSF, ascorbate 
enters the brain interstitium via diffusion. 
 
 
The functions of ascorbate in the CNS and brain are numerous, but incompletely 
understood. Ascorbate acts directly to scavenge oxygen or nitrogen-based 
radical species generated during normal cellular metabolism. It can prevent lipid 
peroxidation, especially in combination with vitamin E, and acts to recycle vitamin 
E in membranes. Ascorbate is thought to have an effect on neural maturation 
and has been proposed to have function as a neuromodulator of both dopamine 
and glutamate-mediated neurotransmission.159  There is also evidence that 
ascorbate is involved in the regulation of both acetylcholine and catecholamine 
release form synaptic vesicles.160 
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In 1983 Hoffer proposed that ascorbate might be useful as a protection against 
auto oxidation damage in critical brain areas.161 This work prompted interest in 
the use of vitamin C in Parkinson’s and Alzheimer’s diseases.  In 1979 Fahn and 
others form the movement disorders specialist’s community started to consider 
the endogenous toxin hypothesis as a plausible mechanism for the causation of 
PD. They began to study whether high dosages of lipid and water soluble 
antioxidants might slow the progression of the disease by increasing the 
scavenging of oxyradicals in the brain. In a small open-label trial, patients with a 
diagnosis of early PD who had not yet started on levodopa therapy, were started 
on vitamin E (α-tocopherol), 3200mg and vitamin C, 3000mg daily in four divided 
doses.  Progression of their PD was measured using the Columbia PD Rating 
Scale and the Schwab-England Activities of Daily Living Scale. Patients were 
started on levodopa therapy only when symptoms become a threat to 
occupational, physical, or social disability. The primary endpoint of the study was 
time to required levadopa or a dopamine agonist. The mean ±SEM duration of 
PD before starting dopaminergics was 71.9 ±6.5 in the group with age of onset of 
PD <54 years. The mean ± SEM duration of PD before starting dopaminergics 
was 63.3 ± 3.9 in the group with age of onset of PD >53.  This patient group, 
treated with antioxidants was compared with another group of early PD patients, 
treated similarly by another physician except that they did not receive antioxidant 
therapy. The mean duration of PD before starting on levadopa or a dopamine 
agonist was 40 months and 24 months respectively.162  Although this trial was not 
a controlled trial, it did appear to indicate that the antioxidant treatment could 
40  
have potential in delaying the end point of initiation of levodopa to treat the 
disease, and a large, double-blind trial of antioxidants was seemingly warranted. 
 
 
Since oxidative stress is an important feature of Alzheimer’s disease (AD), the 
antioxidant capabilities of Vitamin C received attention from those treating AD as 
well.  Low concentrations of antioxidant vitamins C and E have been observed in 
cerebrospinal fluid (CSF) of AD patients. Kontush et al examined the effect of 
vitamin C and vitamin E on lipoprotein oxidation in 20 patients with AD.163 20 
patients were supplemented with either a combination of 400 IU vitamin E and 
100mg vitamin C or 400 IU of vitamin E alone. Supplementation with vitamin E 
and C significantly increased the concentration of both vitamins in plasma and 
CSF, and the abnormally low concentrations of vitamin C were returned to  
normal following treatment. Supplementation with both vitamin C and E also 
significantly decreased the susceptibility of the CSF and plasma lipoproteins to in 
vitro oxidation, whereas supplementation with vitamin E only was unable to have 
an effect on lipoprotein oxidizability, even though CSF and plasma  
concentrations were increased.  The investigators explain the superiority of the 
combined supplementation with vitamins E and C over the supplementation with 
vitamin E alone by suggesting that ascorbate is a physiologically important co- 
antioxidant of vitamin E (α-tocopherol). The major mechanism of antioxidant 
action of α-tocopherol includes inactivation of one free radical by one molecule of 
α-tocopherol with a subsequent scavenging of a second radical by the α- 
tocopherol radical formed.164 
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This mechanism is operative under conditions of high oxidative stress. However, 
the activity of α-tocopherol becomes pro-oxidant under mild oxidative conditions. 
If no additional free radical interacts with the α-tocopheroxyl radical, it can directly 
oxidize lipoprotein moieties itself. Therefore, α-tocopheroxyl radicals must be 
efficiently eliminated from the lipoprotein particle to allow it to develop its 
antioxidant activity.  Elimination of α-tocopheroxyl radical by recycling it directly 
back into α-tocopherol represents an important mechanism of action of co- 
antioxidants like ascorbate.165 
 
 
Animal studies of the effect of ascorbate in Huntington’s disease have also 
shown some promise. Mice that express the gene for Huntington’s disease show 
a deficit in striatal ascorbate release during periods of behavioral activity.  This 
deficit was reversed with ascorbate injections, which also improved the 
behavioral phenotype of repetitive movements.166,167 This animal work continues, 
but no clinical trials have been conducted to date. 
 
 
2.1.3 Coenzyme Q10 
 
Also known as ubiquinone, coenzyme q10 (CoQ10) is an essential cofactor 
serving as an electron acceptor for mitochondrial complex I.  It is also a potent 
antioxidant in lipid membranes and mitochondria.  Studies have shown 
decreased CoQ10 levels in PD patients that induces alteration in ATP synthesis 
and damage of the mitochondrial membrane.168 The first clinical trial was 
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completed for coenzyme Q10 using dosages of 300, 600, and 1200 mg/day. This 
placebo controlled, randomized investigation enrolled 80 otherwise untreated PD 
subjects for 16 months of study drug administration. The primary endpoint was 
the perceived need for initiation of levodopa, and a secondary endpoint was 
change in UPDRS score. A positive outcome was found for subjects receiving 
1200 mg of coenzyme Q10 per day (but not the 300 and 600 mg/day regimens). 
This consisted of an improvement of 6.7 points (p = 0.0416) in the adjusted mean 
score for total UPDRS score. The comparison with placebo treatment was not 
statistically significant, although a pre-specified endpoint of a positive trend was 
achieved.169 Review of the data revealed that most of the benefit observed with 
the highest dose of coenzyme Q10 was derived from its effect for United 
Parkinson disease rating scale (UPDRS) Part 2–Activities of Daily Living, rather 
than to improvement in the motor examination for parkinsonism, UPDRS Part 3– 
Motor Score. These intriguing results provided great interest in linking the 
mitochondrial electron chain transfer defect with a possibly correctable 
mechanism for causation of PD. Because coenzyme Q10 also has antioxidant 
properties, other actions accounting for its disease-modifying effects are 
plausible. The authors reporting these findings emphasized that further study of 
the effects of coenzyme Q10 were warranted before any recommendation as to 
therapeutic use could be made.169 
 
 
Further investigation of coenzyme Q10 was performed in a NET-PD clinical trial 
using 2400 mg/day.23 That dose was one arm of a randomized, placebo- 
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controlled futility trial linked with investigational compound GPI-1485. Subjects 
who did not need and were not receiving symptomatic treatment of PD were 
randomized 1:1:1 among the three treatment assignments (CoQ10, placebo, 
GPI-1485). The primary outcome measure was the change in total UPDRS score 
over 12 months from baseline to disability requiring dopaminergic therapy. A 
number of ratings were conducted in the testing battery in addition to the 
UPDRS, including measures of depression, cognitive function, quality of life, and 
disability. Five time points after baseline (1, 3, 6, 9, and 12 months) were used  
for the testing battery assessing treatment effects. A total of 213 subjects were 
randomized to the three treatment arms. The mean change in UPDRS score in 
the group that received coenzyme Q10 was 7.52 (SD: 8.87). Compared with the 
preset threshold value of 7.46 for progression of PD, found in a previous 
placebo-controlled study of otherwise untreated parkinsonism (DATATOP), 
coenzyme Q10 treatment could not be rejected as futile (p ≤ 0.1). Hence, the 
study recommended that an additional definitive trial was warranted.170 
 
 
In support of this conclusion, a randomized placebo controlled clinical trial with 
Coenzyme Q10 in mild PD was conducted in North America.  Six hundred 
participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 
2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.  
Participants were observed for 16 months or until a disability requiring 
dopaminergic treatment. The prospectively defined primary outcome measure 
was the change in total UPDRS score (Parts I-III) from baseline to final visit. A 
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total of 267 participants required treatment (94 received placebo, 87 received 
1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10. Treatments were 
well tolerated with no safety concerns. The study was terminated after a pre- 
specified futility criterion was reached. At study termination, both active treatment 
groups showed slight adverse trends relative to placebo. Adjusted mean changes 
(worsening) in total UPDRS scores from baseline to final visit were 6.9 points 
(placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 
points (2400 mg/d of CoQ10; P = .21 relative to placebo). Coenzyme Q10 was 
safe and well tolerated in this population, but showed no evidence of clinical 
benefit.171 
 
 
2.2. N-acetylcysteine (NAC) 
 
 
2.2.1 History 
NAC was first reported to have clinical benefit in the early 1960’s, when it was 
shown to be an effective mucolytic agent in patients with cystic fibrosis (CF).172 
This discovery arose from the need to deliver reduced sulfhydryl compounds to 
effect the disruption of disulfide bridges within the glycoprotein matrix of mucous 
in CF patients.  The amino acid residue, L-cysteine was an obvious candidate for 
such an agent, but unfortunately, it is susceptible to metabolism and undergoes 
rapid oxidation in solution, generating the inactive disulfide, cystine.  Acetylation 
of the N-terminal of cysteine was found to confer sufficient stability to the 
molecule to facilitate delivery of reduced sulfhydryl or thiol molecules to work 
effectively as a mucolytic agent in this clinical setting.  .N-acetylcysteine 
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(Mucomyst) was first approved by the FDA in 1963 as a new molecular entity and 
was given priority review (NDA 013601).  Mucomyst is a solution for inhalation 
and is indicated as adjuvant therapy for patients with abnormal, viscid, or 
inspissated mucous secretions in such conditions as: Chronic bronchopulmonary 
disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic 
bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung), 
acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis), 
pulmonary complications of cystic fibrosis, tracheostomy care, pulmonary 
complications associated with surgery, use during anesthesia, post-traumatic 
chest conditions, atelectasis due to mucous obstruction and diagnostic bronchial 
studies (bronchograms, bronchospirometry, and bronchial wedge 
catheterization).173 Today there are multiple generic manufacturers of Mucomyst. 
 
 
A new and important role for NAC emerged after subsequent studies 
investigating its therapeutic potential in acetaminophen poisoning.174,175 The 
mechanism of action in this setting was similar to that for CF: delivery of 
sulfhydryl moieties. However, the mode of action of NAC in acetaminophen 
overdose was thought to rely not only on the ability of NAC to offer some 
protection against oxidation, but also through facilitation of rapid membrane 
permeability due to reduced polarity of the molecule compared to the parent 
amino acid, cysteine. Cleavage of the acetyl group is thought to reveal free, 
reduced cysteine, which is then available for incorporation into the highly 
abundant intracellular antioxidant, glutathione.  The benefit in the setting of 
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acetaminophen overdose is to replenish hepatic GSH that has become depleted 
through the use of the tripeptide in the drug detoxification process.  That NAC 
remains the treatment of choice more than 50 years after its first use is a 
testament both to the importance of maintaining cellular GSH reserves and to the 
exceptional qualities of NAC in helping to replenish this key antioxidant when it 
becomes depleted. In 2004, the intravenous solution of acetylcysteine became 
available as Acetadote. This formulation is FDA-approved to be administered 
intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic 
quantity of acetaminophen, and is indicated to prevent or lessen hepatic injury. 
Since marketing exclusivity for Acetadote expired in 2011, there is now a generic 
manufacturer, InnoPharma, Inc., which manufactures both the acetylcysteine 
solution for inhalation and the intravenous formulation.173 
 
 
2.2.2 Physical/Chemical Properties 
 
 
Acetylcysteine is the N-acetyl derivative of the naturally-occurring amino acid, 
cysteine. The compound is a white crystalline powder with the molecular formula 
C5H9NO3S, a molecular weight of 163.2, and chemical name of N-acetyl-L- 
cysteine. Acetylcysteine has the chemical structure as shown: 173 
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Figure 1. Chemical structure of N-acetylcysteine 
 
 
 
2.2.3 Pharmacology of N-acetylcysteine 
 
Over the past several decades, NAC has been studied for numerous and varied 
potential therapeutic effects. Although the complete mechanisms of its action are 
as yet unclear, the beneficial effects of NAC have been postulated to include: 
transmitter effects, redox modulation, neurogenesis, mitochondrial function, 
immunomodulation and anti-inflammatory activity 
 
 
NAC modulates several key neurotransmitter systems that are known to be 
involved in a range of psychopathology, including glutamate and dopamine.176 
Regulation of glutamate synthesis, release, synaptic levels, and recycling is 
tightly controlled, and dysfunction of this system is implicated in many 
neuropsychiatric disorders including schizophrenia177 and addiction.178 Excessive 
activation of the N-methyl-D-aspartate (NMDA) glutamate receptor is central to 
the excitotoxic damage associated with many forms of neuronal damage and 
degeneration.179 The cystine/glutamate antiporter, or x(c)-system, is a key 
element in the control of extracellular glutamate and feedback regulation of 
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glutamate release.180 Predominantly expressed in astrocytes in the brain, activity 
of this transporter is the primary determinant of non-vesicular release of 
glutamate. The extracellular glutamate activates metabotropic glutamate 
receptors (mGluR2/3) on presynaptic neurons and regulates vesicular glutamate 
neurotransmission.180 
 
 
NAC administration can activate the cystine/ glutamate antiporter through 
provision of additional cystine, thus modulating glutamatergic neurotransmission. 
Through regulation of this system, NAC has been thought to show beneficial 
effects in models of schizophrenia, ameliorating behavioral deficits and reversing 
elevations of extracellular glutamate.181 
 
 
In addition to regulation of glutamate release, NAC, either via GSH or its 
derivatives, has the capacity to modulate NMDA activity.182 Early studies 
suggested that this was through direct binding of the NMDA receptor but more 
recent reports focus on modulation of redox state by GSH. Given the central role 
of glutamate signaling in multiple neuropsychiatric disorders it is likely that this 
activity of NAC is a key component of its therapeutic effect, and explains the 
rapid increase in clinical studies of NAC in neuropsychiatric disorders in recent 
years. 
 
 
Given that dopamine has historically played a lead role in theories underpinning 
the pathology of many neuropsychiatric disorders (e.g., schizophrenia and 
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Parkinson’s disease), the ability of NAC to modulate dopamine is important. NAC 
regulation of the cystine/glutamate antiporter and mGluR2/3 as described above 
can also regulate dopamine release from presynaptic terminals.180   NAC may 
also regulate dopamine release via modulation of the redox status of the cell, via 
the antioxidant effects of GSH and L-cysteine.183 Dopamine itself is strongly pro- 
oxidant, forming hydrogen peroxide (H2O2) and free radicals through auto- 
oxidation and normal metabolism, and hence dysregulation of dopamine 
signaling is thought to be a major contributor to neurotoxicity.184 
Methamphetamine has been shown to evoke strong dopamine release and drive 
neuronal apoptosis. NAC ameliorates the oxidative stress induced by 
methamphetamine production and prevents the down regulation of the dopamine 
transporter elicited by excessive dopamine release.185 These results not only 
highlight the therapeutic effects of NAC but also demonstrate the importance of 
cystine/glutamate transport and GSH regulation of oxidative stress in 
dopaminergic signaling.186 
 
 
The most-studied aspect of NAC is its role in oxidative homeostasis. GSH levels 
are efficiently restored by NAC,187  which acts as a donor of cysteine, the rate- 
limiting component of GSH synthesis. NAC is also effective in reversing the 
oxidative stress associated with mitochondrial dysfunction.188 Approximately 2- 
5% of oxygen passing through the electron transport system inside the 
mitochondria results in superoxide. Superoxide is the most well-known of the free 
radicals as it is commonly produced during the natural pathway of oxidative 
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phosphorylation.189 ROS are produced primarily by the mitochondria as a by- 
product of normal cell metabolism during conversion of molecular oxygen to 
water.  These include superoxide radical, hydrogen peroxide and hydroxyl 
radical.  NAC is an effective free radical scavenger as well as a major contributor 
to maintenance of cellular GSH status, thereby correcting or preventing GSH 
depletion.189  NAC also contributes to the maintenance of oxidative balance 
through the actions of the cysteine/cystine cycle. Similar to GSH and GSSG, 
cysteine and cystine are coupled redox partners which help to prevent oxidative 
cellular dysfunction and injury.190  Hence, the actions of NAC are multifold and 
inter-related, with the production of GSH, the cysteine/cystine cycle, and the 
action of the glutamate/cystine antiporter contributing to maintenance of oxidative 
balance and cellular function. 
 
 
Another potential therapeutic avenue for NAC stems from its anti-inflammatory 
properties. Dysregulation of inflammatory pathways and cytokine levels in both 
the peripheral and the central nervous system (CNS) are associated with 
neuropsychiatric disorders. NAC has been shown to reduce IL-6 levels in 
hemodialysis patients191 and tumor necrosis factor-a (TNF-a) and IL-1b in 
patients undergoing surgery.192 NAC also suppresses production of multiple 
inflammatory cytokines in burn patients.193   In rat models of both traumatic brain 
Injury and focal cerebral ischemia, increased TNF-a and IL-1b levels were 
reduced following NAC administration.194,195 
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Administration of lipopolysaccharide (LPS), a bacterial endotoxin, induces 
widespread inflammation and depressive-like symptoms in animal models. 
However, NAC pretreatment prevents the upregulation of inflammatory cytokines 
in the brain in response to LPS.196 Furthermore, sensitization to hypoxic brain 
injury by LPS and markers of cerebral inflammation are prevented by NAC 
treatment.197 The capacity for NAC to reduce neuroinflammation may be through 
inhibition of the brain inflammatory cells, the microglia. Microglia are brain 
macrophage-like cells which can be activated by cytokines and in turn produce 
inflammatory mediators, induce oxidative stress, and promote neurotoxicity.198 
NAC can inhibit activation, cytokine production, and oxidative species production 
by macrophages and microglia.199 This effect is likely to be through both 
stimulation of GSH production and regulation of cystine/glutamate antiporters, 
regulating oxidative stress and glutamate excitotoxicity.200 
 
 
Overwhelming data support the immuno-modulatory activity of NAC. Clinically, 
NAC improved the ocular symptoms of subjects with Sjogren's syndrome,201 
enhanced natural killer and T-cell function, and delayed the reduction in CD4+ 
levels in HIV patients.202  Administration of NAC to post-menopausal women 
improved immune functions as exhibited by enhanced phagocytic capacity, 
leukocytes chemotaxis, natural killer function, and decreased TNF-α and 
interleukin-8 (IL-8) levels.203 NAC was also proven beneficial in patients with the 
autoimmune disorder systematic lupus erythematosus (SLE). In these patients, 
the mechanism underlying NAC activity was ascribed to a blockade of the 
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mammalian target of rapamycin (mTOR) in T lymphocytes. Activation of mTOR 
occurs upon GSH depletion or after exposure to NO, which causes mitochondrial 
hyperpolarization and can lead to down-regulation of transcription factors and 
subsequent decline in CD4+, CD25+ T cell population. NAC blocked the 
activation of mTOR and increased the number of T lymphocytes.204 Similar in 
vitro enhancement of T-cell growth and function (production of IL-2) was 
demonstrated when peripheral blood T cells were treated with NAC.205 
The molecular mechanisms by which NAC exerts its diverse effects are complex 
and still largely unclear. NAC has been shown to interact with numerous 
biochemical pathways. It is very likely that the effects described so far only 
partially explain the divergent biological effects of NAC, and further studies are 
required for determining its ability to cross the cell membrane and the blood– 
brain barrier as well as elucidating its role in cell signaling pathways. 
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2.2.4 Pharmacokinetics of N-acetylcysteine 
 
 
Pharmacokinetic parameters of orally and intravenously administered NAC have 
been determined in several studies of healthy adults,206,207 adult patients with 
acetaminophen overdosage,208 pregnant women, and preterm and near-term 
infants.209,210 Pharmacokinetic parameters determined in these studies are 
summarized in Table 1.  The results of these studies have varied depending on 
the analytical methods used, dose, formulation, sample collection timing and 
route of administration. 
 
Table 1. Published NAC pharmacokinetic parameters 
 
 
 
Study 
 
Dose 
 
Form 
 
Mean t1/2 
(h) 
 
Mean 
CL 
(L/h/kg) 
 
Mean Vss 
L/kg 
 
Borgstrom et al 
1986206 
 
10 adult 
healthy 
volunteers 
 
600 mg iv 
600mg oral 
 
Non- 
protein- 
bound 
NAC 
 
2.27 iv 
(elimination) 
 
0.211 
 
0.33 
 
Olsson  et  al, 
1988207 
 
200mg iv 
 
 
400 mg oral* 
 
Total 
NAC 
 
5.58 iv 
(terminal) 
 
0.11 
 
0.47 
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6 healthy 
volunteers 
     
 
Prescott et 
al1989208 
 
17 patients with 
Acetaminophen 
overdose 
 
150mg/kg 
over 15 mins 
followed by 
50mg/kg in 4 
h, and 
100mg/kg 
over 16h 
 
Total 
NAC 
 
5.7 (±2.9) 
 
(terminal) 
 
0.19 
 
0.54 
 
Ahola et al, 
1999210 
 
10 preterm 
infants 
 
4.2mg/kg/h 
for 24 h 
(continuous 
infusion) 
 
Total 
NAC 
 
11 
 
(elimination) 
 
0.037 
 
.57 
 
Weist et al. 
 
 
 
 
 
 
100mg/kg iv 
 
Total 
 
 
 
 
 
 
 
 
 
1.2 
 
 
 
 
 
 
 
 
 
0.26 
 
 
 
 
 
 
 
 
 
0.41 
2014209 NAC 
 
11 pregnant 
 
women,  
 q4h 
  
5 preterm     
 12.5mg/kg    
infants,  7.5 0.045 0.47 
q12h 
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6 near term 
infants 
 
25mg/kg 
q12h 
  
5.1 
 
0.07 
 
0.34 
 
* Oral bioavailability of total NAC: 9.1% 
 
 
 
2.2.5 Clinical use of N-acetylcysteine 
 
 
Although the FDA-approved indications for the use of NAC are as a mucolytic 
and as an antidote for acetaminophen overdose, NAC has been studied in a wide 
variety of therapeutic areas for multiple indications over the last several decades. 
A recent search of NAC on clinicaltrials.gov, showed 286 clinical trials in varying 
stages of completion. The subject of these studies continues to be quite varied; 
Smoking cessation, alcohol dependence, pathological gambling, sickle cell 
disease, renal failure, intra-amniotic infection, autism, self-injurious behavior, 
bipolar disorder, polycystic ovary disease, cognitive dysfunction, schizophrenia, 
neurotoxicity of chemotherapy, pulmonary fibrosis, neuronal ceroid lipofuscinosis, 
metabolic disorders, opioid abstinence, and fingernail biting are just a short list of 
the areas being studied with NAC either alone or as adjunct therapy.211 In recent 
years, the role of NAC in the treatment of psychiatric and neurologic disorders 
has attracted the attention of researchers as well as clinicians. In the following 
chapters, the focus will turn to the role of NAC in two neurodegenerative 
disorders in which NAC may play an important role. 
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Chapter 3 
 
Pharmacology of Intravenous N-acetylcysteine with 
Hematopoietic Cell Transplantation in Pediatric Inherited 
Metabolic Disorders 
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3.1 Background 
 
Since the 1980s, hematopoietic cell transplantation (HCT) has been used as a 
treatment for metabolic disorders.  For lysosomal disorders, stable engraftment 
following transplantation has the potential to provide a source of a necessary 
enzyme for the life of the patient. Recombinant enzyme replacement therapy is 
available for those disorders that do not have a primary neurologic component. 
However for diseases affecting the CNS, intravenous enzyme is ineffective due 
to its inability to cross the blood-brain-barrier. For disorders such as 
adrenoleukodystrophy, specifically the cerebral form of ALD, HCT remains the 
only effective form of treatment. In ALD, however, the phenotype and extent of 
disease at the time of transplantation are of fundamental importance in 
determining outcomes after transplant. In 2004, Peters et al reported on the 
international HCT experience and showed that pre-HCT magnetic resonance 
imaging (MRI) severity scores and measures of disability, such as the ALD- 
Disability Rating Scale (ALD-DRS), developed at the University of Minnesota, 
showed marked differences in outcomes after transplant.212  Boys with advanced 
disease, and therefore higher MRI (Loes) scores and higher disability rating 
scores had worse outcomes after HCT. As a result of this data from the 
international experience, HCT was subsequently generally reserved for early 
stage cerebral ALD.  Meanwhile, the University of Minnesota’s Pediatric Blood 
and Marrow Transplantation (BMT) Program had developed a national, if not 
international reputation as being a leader in HCT for metabolic and other 
disorders. Therefore, boys with a new diagnosis of ALD were often referred to 
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the University of Minnesota’s program, often after having a delayed diagnosis, 
and therefore often presented with advanced disease.  Physicians at the 
University of Minnesota’s BMT program were faced with having no alternative 
treatment for those patients referred to them with late-stage ALD. 
 
 
Based on the work of Powers et al, who showed that oxidative stress played a 
key role in ALD as assessed by standard biochemical and immunohistochemical 
markers in the ALD-mouse model as well as ALD patients,213 physicians turned 
to NAC as a potential adjunctive therapy with HCT in late-stage ALD.  The choice 
of NAC was based on the premise that NAC was a well-known, generally safe 
antioxidant with established, safe dosing for children. The initial study included 
three boys approximately 10 years old with a confirmed diagnosis of ALD and 
Loes scores of > 14 who were administered an initial NAC 140mg/kg intravenous 
infusion followed by 70mg/kg four times per day either orally or iv, per an 
approved BMT protocol. All three of the boys treated with adjunctive NAC  
therapy were surviving at 8-11 months post BMT, compared to zero of 8 boys, 
also with severe ALD, who were previously treated with HCT alone.214 The 
difference in survival rates at 12 months post-transplant between these groups of 
young boys, both with advanced ALD, spurred clinician/researchers at the 
University’s BMT program to investigate the use of NAC in ALD. 
 
 
The Center for Orphan Drug Research at the University of Minnesota (Dr. James 
Cloyd) was contacted by the pediatric neurologist (Dr. Laurence Charnas) who 
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was involved in the NAC study. After a short afternoon discussion in which the 
data from the small, 3-patient NAC study were discussed, it was decided that a 
larger study of the pharmacology of NAC was necessary.  Thus began my 
involvement with the study of NAC in ALD and other metabolic disorders with 
neurologic effects. 
 
 
3.2 My Role in This Study 
 
 Assisted in design of the pharmacokinetic studies, based on review 
of existing literature on PK of NAC 
 Assisted in incorporation of PK elements into existing BMT 
protocols for metabolic disorders (both early stage and late-stage 
disease protocols) 
 Co-wrote grants for supplemental funding 
 
o NIH/ NICHD R21 (PAR 06-342: Innovative Therapies & 
Clinical Studies for Screenable Disorders)- not funded 
o AHC- University of MN- funded 
 
 Collaborated with study nurses to incorporate PK protocol into BMT 
protocol for floor nurses 
 Training of BMT floor nurses during all shifts regarding the protocol 
and need for timing and handling of blood samples in the clinical 
setting, forms, etc. 
 Timely pick up and transport of all blood samples from BMT floor to 
 
CODR 
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 Initial sample preparation 
 
 Blood sample analysis (with CODR scientist) 
 
 PK and safety data analysis 
 
 Writing of draft manuscript (not yet published) 
 
 
 
3.3 Introduction and Study Objectives 
 
The inherited metabolic disorders included in this study are lysosomal storage 
diseases (LSD) and ALD.  The inherited lysosomal storage diseases included are 
mucopolysaccharidosis Type I (MPS 1, Hurler’s Syndrome), MPS VI (Maroteaux- 
Lamy Syndrome). These LSDs involve a deficit in the lysosomal enzymes, alpha- 
L-iduronidase and aryl sulfatase-B, respectively, resulting in accumulation of 
glycosaminoglycans, increase in oxidative stress, and resultant damage to 
organs, including heart, lung, liver spleen and central nervous system.215 
Mucolipidosis I (Sialidosis) is another lysosomal storage disease in which the 
enzyme neuraminidase is deficient, resulting in accumulation of sialic acid and 
damage to the CNS.216 Based on the premise that the antioxidant properties of 
NAC could be helpful in all of these inherited metabolic disorders,217 the  NAC 
pharmacokinetic (PK) study protocol was integrated into the existing BMT study 
protocol for these patients. 
 
While NAC may have clinical utility as an adjunctive therapy in LSDs and ALD, in 
order to develop clinical trials to assess efficacy and to optimize dosing 
regimens, pharmacokinetic studies in children, and in these specific populations 
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are required to answer the following questions: 1.) How do the pharmacokinetic 
parameters of iv NAC in these patients differ from that of healthy adults and pre- 
term newborns? 2.) Does the preparatory regimen for HCT alter these PK 
parameters?  3.) How does the HCT itself alter the PK parameters?  4) Does 
NAC infusion result in increased plasma and red blood cell concentrations of 
glutathione? The objective of this study was to determine PK parameters and 
examine the pharmacology of NAC in these patients, in an attempt to answer 
these important questions. 
 
 
3.4 Methods 
 
The study was approved by the University of Minnesota Human Research 
Protection Program and was listed on clinicaltrials.gov: Standard risk protocol: 
NCT 00668564, High risk protocol: NCT 01626092 
 
 
Subjects 
 
Written informed consent was obtained for all study participants prior to 
enrollment. A total of 20 children were enrolled in the study: 18 males, 2 
females, ages 2-15 years. Participants were diagnosed with ALD (n=17) MPS I 
(n=1), MPS VI (n=1) or Mucolipidosis I (n=1) prior to enrollment based on plasma 
VLCFA, enzyme assays or cell cultures. Subject characteristics and blood 
samples analyzed are shown in Table 2. 
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Table 2. Subject characteristics and blood samples analyzed 
 
 
 
 
Subject 
Number 
  Plasma Red Blood Cells 
Diagnosis NAC 
 
Dose 
(mg) 
 
AUC 
1 
 
AUC 
2 
 
AUC 
3 
 
AUC 
1 
 
AUC 
2 
 
AUC 
3 
1 MPS VI 1650 x x x    
2 ALD 2800 x x x    
3 ALD 1750 x x x    
4 ALD 2000 x x x    
5 ALD 2000 x x x    
6 ALD 1700 x x x    
7 Mucolipidosis I 4000 x x  x x  
8 ALD 1800 x x     
9 ALD 1700 x x x    
10 ALD 1400 x x  x x  
11 ALD 1540 x x x    
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12 ALD 1400     x x 
13 ALD 2000  x x  x x 
14 ALD 1400  x x  x x 
15 ALD 3000  x x    
16 ALD 2500  x x    
17 ALD 2000  x x  x x 
18 ALD 2300  x x  x x 
19 ALD 3000  x x  x x 
20 MPS I 1000  x x    
 
 
 
Study Protocols 
 
Based on disease progression and assessment of post-transplant morbidity and 
mortality risk, participants were assigned to one of two study protocols.  High risk 
participants (n=12) were enrolled in the high risk, reduced intensity protocol, with 
HCT occurring on day 0. Subjects were admitted 12 days prior to HCT. The HCT 
preparatory regimen consisted of Campath-1H on day-12 through Day-8, 
continuous infusion of ondansetron beginning on day-7, clofarabine on day-7 
through day-3, Cyclosporin A therapy beginning on day-3 through day+100, and 
a single infusion of melphalan on day-2. Total body irradiation dose was given in 
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a single fraction on day -1. Post-transplant immune suppression included 
mycophenylate mofetil (MMF) day -3 through day 30, and cyclosporine (CSA), 
day -3 through day 100. NAC was administered from day -12 through day 100. 
 
 
A standard risk protocol was used for those participants with less advanced, 
lower-risk disease (N=8).  The preparatory regimen consisted of the following: 
Campath-IH on days -21 through -19, cyclophosphamide, days -9 through -6, 
busulfan, days -5 through -2. Day -1 was a rest day with no treatment. HCT 
occurred on Day 0. Post-transplant immune suppression included MMF day -3 
through day +42, CsA day -3 through day 100-180 (depending on the source of 
donor cells).  NAC was administered from day +1 through day +100. 
 
 
In both protocols, intravenous NAC, 70mg/kg was infused over one hour every 6 
hours until the participant was discharged from the hospital. After discharge, 
administration intervals were adjusted to three times daily using the same dose, 
and were administered by home health nurses. 
 
 
Blood samples were collected on Day-7 (AUC 1) at 0.25,0.5,1,2,3,5 and 8 hrs 
post infusion, Day+7, (AUC 2) at 0.25, 0.5,1,2,3 and 5 hrs post infusion,  and 
Day+21 (AUC 3) at 0.25, 0.5 ,1,2,3 and 5 hrs post infusion, as noted in Table 2. 
Red blood cells and plasma were separated and frozen at -20oC until analysis. 
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Sample Analysis 
 
Plasma and red blood cell samples were analyzed by electrospray ionization 
(ESI) using a Hewlett-Packard 1100 series high performance liquid 
chromatographer with a quadropole mass spectrometer (HPLC/MS) (Agilent 
Technologies, Santa Clara, CA) and a validated assay consisting of quality 
control (QC) standards, calibration standards, and internal standards. Briefly, 
analytes were separated using a Zorbax Eclipse (Agilent Technologies) XDB C18 
column (150 x 3.0 mm, 3.5µ particle size) with a mobile phase consisting of 20 
mM ammonium formate buffer (pH 3.5) and acetonitrile (Sigma; 98:2 vol/vol). 
Analytes were detected in negative ion mode with quantitation ions at m/z 120, 
m/z 162 and m/z 306 for Cys, NAC, and GSH, respectively. The deuterated  
forms of Cys, NAC, and GSH were used as internal standards and quantified at 
m/z 122, m/z 165, and m/z 309, respectively. The flow rate was 0.35 mL/min, and 
the run time was 10 min. 
 
 
Analysis of plasma samples 
 
Plasma QC standards (n=3) were prepared prior to analysis using diluted plasma 
(1:1 with 20mM ammonium formate buffer) and solubilized Cys, NAC, and GSH 
in buffer (range 48-12 µg/mL, 240-640 µg/mL, and 24-80 µg/mL, respectively). 
QC standards were frozen at -20oC until day of analysis. Calibration standards 
consisted of six mixed standards (range of 0-40 µg/mL), two high-concentration 
NAC standards (80 µg/mL and 160 µg/mL), and zero. Volumes for sample 
processing were as follows: 250 µL plasma (subject, QC, or diluted), 50 μL 
66  
internal standard, 100 μL 0.05 mg/mL dithioerythritol (DTE), 100 μL buffer, and 
50 μL calibration standard (if appropriate). The final internal standard 
concentration was 20 µg/mL for deuterated GSH and Cys and 120 µg/mL for 
deuterated NAC. A “blank” plasma sample containing only 250 µL diluted plasma 
was included in assay preparation for subtraction of background. All calibration 
standards were analyzed in triplicate. QC standards were analyzed in 
quadruplicate. 
 
 
All samples were incubated in a water bath for 30 min at 37oC and 85 rpm. 
Following incubation, 2 mL of methanol was added to each tube to precipitate the 
protein.  All samples were centrifuged at 2000 rpm for 10 min. The organic layer 
was conserved and evaporated at 37oC by gaseous nitrogen (15 psi) using a 
TurboVap® LV Concentration Evaporator.  Sample contents were reconstituted 
in 300 μL of buffer and filtered through Acrodisc® nylon syringe filters into HPLC 
vials for analysis. 
 
 
Analysis of red blood cell samples 
 
Red blood cell QC and calibration standards were prepared similarly to plasma 
standards except diluted blood was used as the medium. The QC concentration 
range was 6-50 µg/mL for Cys and NAC (n=3) and 125-450 µg/mL for GSH 
(n=3). The final calibration standard range was 0-100 µg/mL for Cys and NAC 
and 0-500 µg/mL for GSH. Calibration standards were comprised of six mixed 
compound standards, one high NAC standard (500 µg/mL), and zero. Volumes 
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for sample processing were as follows: 50 µL blood (subject, QC, or diluted), 25 
 
µL internal standard, 50 µL red blood cell lysis buffer, 50 µL DTE, and 25 µL 
calibration standard (if appropriate). HPLC grade water (25 µL) was also added 
to QC and patient samples. The final internal standard concentration was 100 
µg/mL for GSH, Cys, and NAC. A “blank” blood sample (no internal or calibration 
standard) was included in assay preparation for subtraction of background. 
Further blood analysis mimicked that of the plasma samples described above. 
 
 
 
Data Analysis 
 
Calibration curves were constructed for each analyte in plasma and blood using 
peak area response ratios of analyte to internal standard and known 
concentration. Concentrations of Cys, NAC, and GSH were calculated from the 
appropriate calibration curve. The lower limit of quantitation was 5 µg/mL for 
NAC and Cys and 50 µg/mL for GSH. 
 
 
Pharmacokinetic Data Analysis 
 
Pharmacokinetic analysis of intravenous NAC was completed with Phoenix 
WinNonlin 6.2 (Pharsight Corporation, Mountain View, CA, USA). Non- 
compartmental analysis was used to calculate area under the curve. Time to 
maximum concentration (Tmax), minimum concentration (Cmin), maximum 
concentration (Cmax), volume of distribution, clearance and half-life were also 
determined. 
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For each PK parameter, the data were analyzed using repeated measures 
analysis of variance (ANOVA) to determine significant differences based on 
dosing period (AUC 1 vs 2 vs 3). Significance was determined at the p < 0.05 
level.  Accuracy and precision data were determined for quality control samples 
for both assays and are reported in table 3. 
 
 
Table 3. Accuracy and precision data for plasma and red blood cell assays 
 
Assay Nominal 
conc. 
(μg/ml) 
NAC(N=20) CYS(N=20) GSH (N=20) 
 A* 
(%) 
P** 
(%CV) 
A* 
(%) 
P** 
(%CV) 
A* 
(%) 
P** 
(%CV) 
Plasma LQC 98.34 9.05 131.73 20.98 86.56 13.0 
MQC 88.72 5.69 85.24 14.98 88.66 9.51 
HQC 90.62 6.12 88.16 8.79 91.21 6.42 
RBCs LQC 106.64 17.9 106.71 23.7 107.41 12 
MQC 95.38 9.8 108.50 24.7 97.45 11.1 
HQC 108.97 10.6 95.47 12.9 95.47 13.3 
A*= accuracy, P**= precision 
 
 
 
3.5 Results 
 
The NAC concentration profiles in plasma and red blood cells following 70 mg/kg 
NAC infusion are shown in Figure 2. The NAC pharmacokinetic parameters are 
reported in Table 4. 
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a. Plasma b. Red Blood Cells 
 
 
  
 
 
Figure 2. NAC concentrations in plasma (a) and red blood cells (b) following 
NAC infusion (70 mg/kg). Values are expressed as mean + standard error of the 
mean (SEM). 
 
 
 
Table 4. Pharmacokinetic parameter values for NAC following 70 mg/kg NAC 
infusion. 
 
 
Parameter 
AUC 1 AUC 2 AUC 3 
Mean (SD), % CV Mean (SD), % CV Mean (SD), % CV 
P
la
s
m
a
 
Cmin 
(µg/mL) 
11 (6), 56 8 (5), 64 9 (8), 95 
Cmax 
(µg/mL) 
157 (189), 120 117 (41), 35 106 (28), 27 
AUC0-6hr 
(hr*µg/mL 
) 
 
313 (266), 85 
 
222 (92), 41 
 
225 (82), 37 
AUC0-inf 
(hr*µg/mL 
) 
 
356 (306), 86 
 
248 (105), 43 
 
249 (92), 37 
t1/2 
(hr) 
1.5 (0.5), 31 1.7 (1.1), 67 1.5 (0.5), 30 
CLss 
(L/hr/kg) 
0.3 (0.15), 49 0.4 (0.2), 50 0.4 (0.2), 50 
Vss 
(L/kg) 
0.81 (0.55), 67 0.80 (0.41), 52 0.80 (0.30), 38 
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 Vz 
(L/kg) 
0.77 (0.53), 69 0.88 (0.61), 69 0.77 (0.40), 51 
R
e
d
 B
lo
o
d
 C
e
ll
s
 
Cmin 
(µg/mL) 
2.2 * 4.4 (2.7), 61 7.0 (4.4), 63 
Cmax 
(µg/mL) 
18.6 * 27 (4.9), 18 35 (12), 36 
AUC0-6hr 
(hr*µg/mL 
) 
 
33 * 
 
61 (21), 35 
 
78 (51), 65 
AUC0-inf 
(hr*µg/mL 
) 
 
40 * 
 
71 (26), 37 
 
108 (80), 74 
t1/2 
(hr) 
1.4 * 2.6 (1.0), 39 2.2 (1.5), 68 
CLss 
(L/hr/kg) 
0.06 * 0.05 (0.02), 32 0.04 (0.02), 55 
Vss 
(L/kg) 
0.14 * 0.16 (0.05), 31 0.10 (0.02), 20 
Vz 
(L/kg) 
0.14 * 0.17 (0.05), 31 0.04 (0.02), 55 
 
 
 
NAC reached maximum plasma concentrations of approximately 157 ug/mL at 
1.5-1.7 hours post start of infusion and maximum red blood cell concentrations of 
35 ug/mL. Red blood cell NAC concentrations ranged from 12-33 % of plasma 
NAC concentrations. Total red blood cell exposure based on AUC0-inf  was 11%, 
29% and 43 % of total plasma exposure for AUC 1, AUC2 and AUC3 
respectively. Half- life of NAC was approximately 1.5 hours and was similar in 
plasma and red blood cells. 
 
 
Mean glutathione concentrations are shown in figure 3. Mean plasma glutathione 
concentrations initially decreased from baseline following NAC infusion. 
Concentrations then rose to at least baseline levels several hours after NAC 
 
infusion. Red blood cell concentrations of glutathione increased slightly after 
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NAC infusion and then stabilized. RBC concentrations were approximately 100 
times that of plasma concentrations, as expected. Increased variability of 
glutathione concentrations was noted, particularly in plasma. Although no overall 
difference was seen in plasma concentrations over AUC 1, AUC 2 and AUC 3, 
an increase in RBC concentrations was observed in AUC 3 versus AUC2. 
 
 
 
 
a. Plasma b. Red blood cells 
 
 
Figure 3. Glutathione concentrations in plasma (a) and red blood cells (b) 
following NAC infusion (70 mg/kg). Values are expressed as mean + standard 
error of the mean (SEM) 
 
 
Cysteine concentration-time profiles are reported in Figure 4. Mean cysteine 
concentrations remained relatively stable after NAC infusion in both plasma and 
red blood cells.  An increase in plasma cysteine concentrations was seen in AUC 
3, but plasma concentrations returned to baseline after 6 hours. 
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a.  Plasma b. Red blood cells 
 
 
 
Figure 4. Cysteine concentrations in plasma (a) and red blood cells (b) following 
NAC infusion (70 mg/kg). Values are expressed as mean + standard error of the 
mean (SEM) 
 
 
No significant differences were found between AUC1, AUC2 and AUC3 in the PK 
parameters AUC, Cmax, half-life, clearance or volume of distribution. 
 
 
Adverse events experienced by the subjects were nausea and vomiting, and 
were considered mild to moderate in severity. With the multiple HCT-related 
medications being administered, it is difficult to determine causality of these 
adverse events.  No serious adverse events were reported during the study and 
no subject discontinued NAC due to adverse events.  There were no allergic or 
anaphylactoid reactions reported during the study. 
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3.6 Discussion 
 
This is the first report of NAC pharmacokinetics in the pediatric population 
undergoing HCT. We report an average half-life of 1.5-1.7 hours +1.1 hr, which 
is similar to that reported in the literature for adults,206,209 but substantially shorter 
than the half-life of 11 hours reported in pre-term newborn infants.210   AUC0-6  and 
AUC 0-12hr were calculated using the concentration data from AUC 1. The AUC 0-6 
was approximately 95% of AUC 0-12. Clearance in these subjects was similar to 
that of pregnant women,209 slightly higher than adult men,206 and 90-150% higher 
than that of preterm newborn infants.209,210 Exposure as measured by AUC0-6hr  
did not appear to be affected by the pre and post- transplant regimen, and 
remained consistent over AUC 1, AUC 2 and AUC 3, before and after HCT. 
 
 
Although no overall difference was seen in plasma glutathione concentrations 
over AUC 1, AUC 2 and AUC 3, an increase in RBC concentrations was 
observed in AUC 3 versus AUC2. This increase may be related to the effects of 
NAC and the provision of cysteine for glutathione synthesis. It may also be the 
effect of HCT itself or recovery from the effects of the peri-transplant regimen. 
 
 
Based on these data, NAC dosing does not appear to result in increased 
cysteine. This lack of effect on cysteine concentrations has been reported by 
others.218 However, there may be some effect of NAC on levels of reduced 
versus oxidized cysteine concentrations or unbound versus bound cysteine, 
therefore increasing the “therapeutically available” concentrations. Likewise with 
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glutathione, NAC may be increasing the availability of reduced glutathione and 
therefore exerting its therapeutic effect. A shortcoming of this study was that total 
cysteine and glutathione were measured.  Future studies that measure both the 
oxidized and reduced forms of cysteine and glutathione may delineate additional 
information on the therapeutic effect of NAC. 
 
 
AUC calculations based on 6 hour concentration data was 95% of the AUC 
based on 12 hr data.  We therefore report a half-life of 1.5 hrs based on 
concentrations to 6 hours which we believe represents the effective half-life of 
NAC. 
 
 
The lack of adverse events experienced by subjects in this study is striking. 
Allergic and anaphyactoid type reactions to N-acetylcysteine are fairly common 
among patients being treated with NAC for acetaminophen overdose.219 
Although the number of subjects in this study was relatively small, we would have 
expected to see at least a few subjects experience an anaphylactoid type adverse 
event.  One potential reason for the lack of these adverse events is the            
fact that the subjects were on immunosuppressants as part of the peri-transplant 
regimen. Overall, NAC appears to be safe and well tolerated in this population. 
 
 
The data from this pharmacokinetic study in children has implications for future 
studies of NAC in pediatric populations undergoing HCT. Pharmacokinetic 
parameters as measured in this study appear to be similar to published data on 
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adults, and remain largely unaffected by the transplant preparatory regimen used 
in this study, or by the transplant itself. Although total cysteine did not appear to 
increase in either plasma or red blood cells as a result of NAC, future studies will 
require measurement of both reduced and oxidized cysteine, to ascertain if there 
is indeed an increase in the reduced, and therefore “available” form of cysteine. 
Likewise, reduced and total glutathione measurements will be helpful in 
determining if the GSH redox ratio is altered as a result of NAC administration. 
 
 
The data from this PK study can be used to guide NAC dosing for additional work 
in this pediatric population to determine the blood and brain effects of NAC in 
those with metabolic disorders with neurologic effects. 
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Chapter 4 
 
Effect of N-acetylcysteine on Brain Glutathione 
Concentrations in Gaucher and Parkinson 
Disease Patients 
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4.1 Rationale for the study of NAC in PD and GD 
 
Although modest increases in intracellular GSH were detected in red blood cells 
after repeated i.v. dosing of NAC in children with metabolic disorders, the effect 
of NAC on brain GSH concentrations remained unknown. Since the effect of 
NAC on neurodegenerative disorders involving oxidative stress is reliant on the 
ability to cross the blood-brain-barrier, the next study of NAC would logically be 
the study of brain effects. Fortunately, modern magnetic resonance 
spectroscopy (MRS) methods allow for the quantification of a number of 
metabolites in the brain, including GSH.220 Although MRS methods have been 
used to assess cerebral lesions in boys with ALD in the past,221 a prolonged, PK/ 
MRS study would not be feasible in this vulnerable population. 
 
 
Since GSH depletion in PD and an impaired adaptive response to oxidative  
stress in GD have both been observed, antioxidants that increase GSH may have 
a protective effect in these disorders. Unfortunately, past PD research using 
intravenously administered GSH failed to provide a definitive benefit.222  This 
failure may be related to a suboptimal dosing regimen, but more likely is due to 
the saturable mechanism for GSH passage across the blood-brain barrier as well 
as a lack of uptake into neurons.223 
 
 
A possible way to boost CNS GSH levels while avoiding the above is to employ 
NAC, a membrane-permeable cysteine precursor which serves as the rate 
limiting substrate for GSH biosynthesis. NAC increases intracellular GSH in 
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human erythrocytes,218 however its effect on human brain GSH concentrations is 
unknown. Despite in vivo studies of NAC in animal models of neurodegenerative 
disease,224,225 and a small clinical trial of oral NAC in patients with late stage 
Alzheimer’s disease,226 it has yet to be shown that NAC can in fact alter GSH 
concentrations in the human brain. We hypothesized that intravenously 
administered NAC increases brain GSH concentrations and blood GSH/GSSG 
ratios. We utilized ultra-high field MRS methodology227 to measure the effect of 
NAC administration on cerebral GSH levels and mass spectrometry to measure 
its effects on blood redox status. 
 
 
4.2 My Role in the Study of Brain Effects of NAC 
 
 Co-wrote 4 grant applications: 
 
 Minnesota Medical Foundation- initial funding 
 
 Minnesota Futures Grant- not funded 
 
 Michael J. Fox Foundation: Repositioning Drugs 
for Parkinson Disease- not funded 
 LDN/NIH Rare Disease Clinical Research Network 
(RDCRN) - funded 
 Designed study with study team 
 
 Wrote study protocol 
 
 IRB application, submission 
 
 IND application/ Request for waiver 
 
 Re-wrote protocol with NIH input 
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 Re-submitted IRB application with changes from NIH 
 
 Developed all case report forms and study manual 
 
 Developed regulatory binder with study expert from 
Neurology department 
 Assisted in development of NIH- compliant patient 
database 
 Study coordinator responsibilities: 
 
 Filed all paperwork with CTSI for nursing staff, trained 
nursing staff 
 Recruited, screened, enrolled, scheduled 
subjects, filed necessary paperwork for 
reimbursement of study participants 
 Prepared study binders for each subject, 
delivered drug order to investigational 
pharmacy 
 Day of study coordination: 
 
 Coordinated study staff, nurses, CMRR 
staff, materials, equipment, exam rooms, 
MRI suite, pick up and transport of study 
drug 
 Met subjects, assisted with consent, 
baseline assessment 
 Administered NAC infusion, coordinated 
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blood sample handling and transport to lab, 
timed study 
 Filed all IRB, NIH/RDCRN paperwork 
 
 Analyzed PK and safety data 
 
 Coordinated Study Audit by NIH/ RDCRN, May 29- 
30,2013 
 
 
4.3 Study Methods 
Subjects 
This study enrolled 3 people with PD, 3 people with GD, and 3 healthy 
controls (HC). The study protocol was approved by the University of 
Minnesota Human Research Protection Program, the National 
Institutes of Neurological Disorders and Stroke (Protocol #6721), and 
was listed on ClinicalTrials.gov: NCT01427517.  All participants gave 
written informed consent before enrollment. Non-demented individuals 
with mild to moderate PD (Hoehn and Yahr stage 2) were recruited 
from the University of Minnesota’s Movement Disorders Center. 
Patients with genetically and metabolically confirmed GD type 1 were 
recruited from the University of Minnesota and the Lysosomal Disease 
Network/NIH. The study included adult male (N=4) and female subjects 
(N=5), age (years), gender and disease classification: PD: 52F, 53F, 
58F; GD: 18M, 50M, 64M; and HC: 58F, 58M, 58F. All subjects were 
on stable treatment regimens for 1 month prior to enrollment.  Use of 
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antioxidant supplements, including coenzyme Q-10 and vitamin E, was 
not allowed within 3 weeks of enrollment. Individuals with a history of 
asthma or bronchospasm were excluded from the study. 
 
 
Clinical Assessments & Study Scheme 
 
Age, ethnicity, gender, disease duration, weight, smoking status, use 
of alcohol and illicit drugs, Unified Parkinson’s Disease Rating Scale 
score (I-III), Hoehn & Yahr staging, Montreal Cognitive Assessment 
Score, medications, supplements and vital signs were recorded at 
baseline. Following collection of a baseline blood sample, the subject 
was placed into the MR scanner to determine the baseline brain GSH 
concentration.  The subject was then removed from the scanner and 
NAC (150 mg/kg) was administered intravenously over 1 hour. The 
subject was placed back into the scanner ~30min following the start of 
infusion and brain GSH measurements and blood samples were 
collected at 15 minute intervals until 1 hour after the end of the 
infusion. 
 
 
MRS Protocol 
 
Brain MR scans were performed using a 7T, 90-cm horizontal bore 
magnet (Siemens MAGNETOM) and a quadrature surface coil, as 
described previously.219 Images acquired with a 2 x 1 x 2 mm 
82  
resolution MPRAGE sequence were used for the selection of the 
volume-of-interest (VOI). All first- and second-order shims were 
adjusted using FASTMAP with echo-planar imaging readout.228   
Spectra were acquired from the occipital cortex (22 x 22 x 22 mm³) with 
a modified semi-LASER sequence (echo time TE = 26 ms,       
repetition time TR = 5 s).229 Unsuppressed water spectra acquired from 
the same VOI were used to remove residual eddy current effects and 
as a quantification reference.  Single-shot data were saved during 
acquisition; individual FIDs were frequency and phase corrected prior 
to summation. 
 
 
Metabolite Quantification 
 
Metabolites were quantified using LCModel230 as described 
before.227,220 The metabolite model spectra were generated based on 
previously reported chemical shifts and coupling constants.231,232 
Macromolecule spectra were acquired from the occipital cortex using 
an inversion recovery sequence (TR = 2 s, inversion time TI = 0.680 
s).233 Metabolites quantified with Cramér-Rao lower bounds (CRLB, 
estimated error of the metabolite quantification) > 50% or correlation 
coefficient < -0.5 were classified as not detected.234 Concentrations 
were not corrected for T1 and T2 effects or cerebrospinal fluid 
contribution to the VOI. 
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GSH/GSSG Redox Ratio 
Sample Collection and Analysis 
Blood samples were collected via a catheter that was placed in the 
subject’s lower leg into a tube containing EDTA. To prevent GSH 
oxidation, 1 mL of whole blood was immediately mixed with 0.5 ml of 
3% meta-phosphoric acid (Sigma). The blood samples were stored at 
4°C and analyzed the same day as blood collection. Fifty microliters of 
blood were extracted with 2 mL of methanol (Fisher). The supernatant 
was evaporated and reconstituted in 300 μL of mobile phase and 
filtered into high performance liquid chromatography vials using 
Acrodisc® nylon syringe filters. The chromatographic system used 
consisted of a Hewlett-Packard 1100 series (Agilent Technologies) 
with a quadrupole mass spectrometer (model G1946A). The analytes 
were separated using a Zorbax Eclipse XDB C18 column (150 mm x 
3.0 mm, 3.5µ particle size) and eluted isocratically with a mobile phase 
consisting of 20 mM ammonium formate (Fluka) buffer (pH 3.5) and 
acetonitrile (Sigma) (98:2, v/v).  The analytes were detected using an 
electrospray ionization-MS system in the positive ion mode 
(quantitation ions: m/z 122, m/z 164, m/z 308, and m/z 613 for 
cysteine, NAC, GSH, and oxidized glutathione, respectively). Each 
sample was analyzed in triplicate. The GSH/GSSG redox ratio was 
determined using the peak area response ratio for GSH and GSSG. 
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GSH/GSSG redox ratio was reported as the mean of the triplicate 
values with all values within 50 percent of the mean. 
 
 
Data Analysis 
 
Percent change from baseline was calculated for both blood 
GSH/GSSG ratios and brain GSH levels for each subject at each time 
point.  Maximal percent change for each subject was determined. 
 
 
4.4 Results 
 
Blood GSH/GSSG ratios increased following the start of NAC infusion, 
reaching a maximum at approximately 60-75 minutes. Brain [GSH] 
also increased with maximal values observed at approximately 90-110 
minutes after the start of infusion. Subjects with the greatest percent 
change in blood GSH/GSSG ratio after NAC infusion also had the 
greatest percent change in brain [GSH], with the exception of subject 
PD03. (Figure 1) The average maximal percent change from baseline 
in brain [GSH] was 55%, 41% and 34% in the PD, GD and HC groups, 
respectively. Although brain [GSH] reached maximal percent change 
from baseline at 90-110 minutes and then began to decline in all 
subjects, none of the subjects had returned to their baseline brain 
[GSH] at 120 minutes post NAC infusion. 
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Figure 5. Blood GSH redox ratio (open squares) and brain GSH 
 
concentrations (closed circles) in PD, GD and healthy control subjects. Blood 
GSH redox ratios for HC 01 and HC02 not shown, due to difficulty with 
GSH/GSSG stabilization prior to bioanalysis. 
 
 
4.5 Discussion 
 
In this proof-of-concept study, we show that brain GSH concentrations 
and blood GSH redox ratios increase following intravenous NAC 
administration and thereby demonstrate the feasibility of altering and 
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monitoring changes in peripheral and central antioxidant status. These 
results support the hypothesis that NAC enhances GSH synthesis in 
the brain. While the ultimate question as to whether altering brain 
[GSH] will affect the course of PD or GD remains unanswered, this 
represents the first demonstration that MRS can measure 
pharmacodynamic changes in response to intravenous NAC 
administration in PD, GD and controls. The [GSH] measured by MRS 
in the occipital cortex VOI also includes the contribution of blood GSH. 
However, blood makes up only ~3 percent of the volume in brain.235 
Thus, the change detected in brain [GSH] in this study could not be 
due primarily to the contribution of blood GSH because the mean 
maximal increase in blood GSH of 30% measured in this study would 
only lead to a MRS voxel [GSH] increase of 0.9%. In addition, the 
maximal change in the brain [GSH] occurred with a ~30 min delay 
relative to the redox change in blood (Figure.1), further substantiating 
the limited effect of blood on the brain measurement. 
 
 
Although the average maximal percent change from baseline in brain 
[GSH] appeared to differ among the subject groups, the number of 
subjects in this study is too small to draw any definitive conclusions. A 
study involving a larger number of subjects is required to determine if 
individuals with PD or GD have altered baseline GSH levels that may 
be due to their subtype or severity of condition, e.g., cortical Lewy 
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pathology in advanced PD, and whether there are differences in the 
change from baseline in brain [GSH] between subject types. In this 
study we focused on the occipital cortex rather than the substantia 
nigra, where a GSH deficit has been detected postmortem in 
PD.236Due to challenges associated with MRS in the substantia nigra in 
humans, including its location, very small size (limiting signal-to- noise 
ratio), and high iron content (giving rise to broad intrinsic linewidths, 
thereby limiting spectral resolution),237,238 we chose the             
occipital cortex to increase our chances of reliably detecting a NAC 
effect on [GSH].  Our results suggest that the effect of NAC on [GSH] 
is global and that NAC is able to increase brain [GSH] even in controls. 
 
 
Following a single intravenous NAC dose, we observed a transient 
increase in blood GSH redox ratio which was attributed to an increase 
in GSH as well as a decrease in GSSG in all subjects. GSSG 
disassociation by NAC, resulting in a NAC-GS complex and free GSH, 
could contribute to the transient nature of this change. Despite a rapid 
decrease in whole blood GSH redox ratios following the end of the 
NAC infusion, [GSH] in the brain remained elevated at 2 hours after 
the start of infusion. It is unknown whether the pharmacologic actions 
of NAC will be the same for oral administration. 
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There are reports of positive effects of oral NAC in disorders with CNS 
involvement.239,240 Future studies are necessary to determine if oral 
NAC affects brain [GSH] and if so, to establish optimal dosage 
regimens to attain sustained elevation of brain [GSH] with repeated 
dosing. 
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Chapter 5 
 
Future Studies of N-acetylcysteine in Neurodegenerative 
Disorders 
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5.1 Studies of Oral N-acetylcysteine 
 
Although our studies show an increase in total brain GSH after NAC 
administration and improved survival outcomes in children with metabolic 
disorders after HCT with adjunctive NAC treatment, i.v. administration is clearly 
not practical for long term treatment with NAC, particularly in the out-patient 
setting. Questions remain however, regarding the bioavailability and therapeutic 
effects of NAC given orally. It is known that oral NAC undergoes extensive first 
pass metabolism, but what is yet unknown is whether its conversion and 
therefore supply of cysteine for the biosynthesis of GSH is the most important 
means of NAC exerting its therapeutic effects. 
 
 
Arfsten et al studied the distribution of radio-labeled NAC (14C-NAC) and its 
impact on glutathione metabolism in Sprague-Dawley rats following single and 
multiple dosing with NAC (1200 mg/kg) by oral gavage.241  They found that 
radioactivity associated with administration of 14C-NAC distributed to most 
tissues examined within 1 hour of administration;  peak radioactivity levels 
occurred within 1 hour to 4 hours and for a majority of the tissues examined, 
radioactivity remained elevated for up to 12 hours or more. Administration of a 
second dose of NAC 4 hours after the first increased liver, kidney, skin, thymus, 
spleen, eye, and serum radioactivity significantly beyond levels achieved 
following 1 dose. Administration of a third dose of NAC + 14C-NAC 4 hours after 
the second dose did not significantly increase tissue radioactivity further except 
in the skin. Interestingly, GSH concentrations were increased 20% in the skin 
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and 50% in the liver after one dose of 1,200 mg/kg NAC whereas lung and 
kidney GSH were unaffected. Administration of a second and third dose of NAC 
at 4 hours and 8 hours after the first did not increase tissue GSH concentrations 
above background with the exception of skin GSH levels, which were elevated to 
levels similar to those obtained after a single dose of NAC. 
 
 
Levels of glutathione-S-transferase (GST), the enzyme responsible for linking 
toxic compounds with GSH, were increased 150% in the kidney and 10% in the 
liver, decreased 60% in the skin, and had no effect on lung GST activity following 
a single dose of 1,200 mg/kg NAC. Administration of a second dose of NAC 4 
hours after the first decreased skin GST activity a further 20% whereas kidney 
GST activity remained elevated at levels similar to those obtained after 1 dose of 
NAC. Administration of a third dose of NAC 4 hours after the second dose 
increased liver GST activity significantly as compared to background but did not 
affect skin, kidney, or lung GST activity. 
 
 
Transient decreases in glutathione reductase (GR) activity were measured in the 
skin and kidney in association with repeat administration of 1,200 mg/kg NAC. 
Glutathione peroxidase (GxP) activity was increased in the skin, kidney, and 
liver, suggesting that oxidative stress was occurring in these tissues in response 
to repeat dosing with NAC. 
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Overall, the results of this study present the possibility that NAC could provide 
some benefit in preventing or reducing toxicity related to oxidative stress in some 
tissues by increasing tissue NAC and/or cysteine levels, GSH concentrations, 
and GST activity. The authors suggest that follow-on studies are necessary and 
that the effect of NAC on increases in GxP needs to be further investigated. 
 
 
Future studies of orally administered NAC could use a stable-labelled, 
nonradioactive NAC to characterize the effects of NAC on intracellular cysteine 
and glutathione concentrations.  Using this technique, one could compare the 
intracellular concentrations of NAC and is metabolic products cysteine and 
glutathione and compare the effects of i.v. versus oral administration to  
determine if oral administration produces the desired treatment effects. Since the 
safety of stable-labelled compounds have been established, these studies could 
be performed in either children with metabolic disorders or adult patients with 
Parkinson or Gaucher disease. If oral administration of NAC is found to         
have similar intracellular and brain effects as i.v. administered NAC, this would 
pave the way for larger scale studies of appropriate oral doses of NAC in patients 
with neurodegenerative and other diseases where glutathione is found to be 
deficient. In the case of ALD, if oral NAC is found to have positive effects on 
intracellular and brain GSH concentrations, oral administration of NAC long-term 
could be a viable option in treatment of newly diagnosed ALD to potentially 
prevent the onset of the cerebral form of the disease, for which there is no known 
cure at present, and it would present an option with a much lower risk than HCT 
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or gene therapy. For those with Parkinson disease or Gaucher disease, oral NAC 
therapy initiated early in the course of disease could represent a treatment option 
to delay or prevent the progression of the disease. 
 
 
5.2 Studies of N-acetylcysteine amide 
 
Despite decades of research on the effects of NAC in numerous and diverse 
disorders, it is still used routinely on a widespread basis only as an antidote for 
acetaminophen toxicity and as a mucolytic. In a recent critical review of NAC, 
the author concluded, “NAC has so far not fulfilled the impressive promises that 
theory and experimental research have put forward, thus it seems to share the 
destiny of other antioxidants”242  Failure of NAC to provide significant effect may 
be due in part to its low oral  bioavailability or its hydrophobicity. At physiological 
pH, NAC acquires a negative charge by losing a proton from the carboxyl group. 
This deprotonation hinders its passage across biological membranes.243 In 
critical oxidative stress conditions, adequate concentrations of NAC may not be 
present to replenish the GSH concentrations. In addition, NAC has been found 
to be pro-oxidant at higher concentrations.244 These limitations may in part 
explain the lack of success in the wide variety of disorders in which NAC has 
been tested. 
 
 
In recent years, lipophilic thiol compounds with improved bioavailability and 
membrane permeability have been proposed.  N-acetylcysteine amide (NACA) is 
one such compound.  NACA is a derivative of NAC in which the carboxyl group is 
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neutralized by an amino group with the expectation of improving the lipophilicity 
and membrane permeability of the compound. A recent study provided evidence 
that NACA had more efficient membrane permeation than NAC and could 
replenish intracellular GSH in red blood cells, possibly by disulphide exchange 
with oxidized glutathione (GSSG).245 NACA was also shown to cross the blood 
brain barrier, scavenge free-radicals, chelate copper, protect red blood cells from 
oxidative stress and attenuate myelin oligodendrocyte glycoprotein (MOG)- 
induced experimental autoimmune encephalomyelitis in a multiple sclerosis 
mouse model.245  NACA is partially metabolized to N-acetylcysteine.246 
 
 
5.2.1 NACA in Alzheimer’s disease 
 
GSH depletion and oxidative stress are believed to play a central role in the 
deterioration of neuronal tissue associated with aging and Alzheimer’s disease 
(AD). It is well established that the protein amyloid-beta (Aβ) plays an important 
role in the pathogenesis of AD and has the ability to induce oxidative stress in 
brain tissue. Prevention of Aβ- induced oxidative stress in brain tissue may 
provide a potential treatment for AD. Bartov et al experimented with NACA in a 
rat model of AD to determine if NACA could protect neuronal cells from the toxic 
effects of Aβ.247 Rat primary neurons were treated with 10µM NACA or saline 
one hour prior to the addition of 10µM Aβ. Cell viability, protein oxidation and lipid 
peroxidation were measured following a 24 hour incubation.  Pretreatment with 
NACA was able to protect rat neuronal cells from the toxic effects of Aβ and 
prevent oxidative damage to neuronal proteins and lipids.  NACA’s ability to 
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protect neuronal cells from the toxic effects and oxidative stress of Aβ provide 
some support for the potential benefit of antioxidant treatment with NACA in AD. 
It should be noted that NAC has been studied in a clinical trial of patients with 
moderate to severe AD to determine if NAC treatment could improve the course 
of neurologic deterioration in AD.226  In the double blind placebo-controlled 
clinical trial of oral NAC, 50mg/kg/day in three divided doses daily was given to 
moderately to severely affected patients.  The primary endpoint was the score on 
the Mini Mental Status Exam (MMSE) and activities of daily living (ADLs). 
Secondary outcomes included various neuropsychological tests. Outcomes were 
compared at 12 and 24 weeks. The active (n=23) and placebo (n=20) groups 
were well matched at baseline. At mid-point evaluation, the analysis showed a 
trend toward a favorable treatment effect on MMSE score in favor of NAC 
(p=0.056). At 24 weeks, patients receiving NAC showed significantly better 
performance on the letter fluency task compared to placebo. Performance on the 
Wechsler Memory Scale immediate figure recall showed a trend toward 
improvement by NAC (p=0.067), but the trial failed to meet its primary endpoint. 
Several factors may have affected the results of this trial: 1.) the study was likely 
underpowered to see a treatment effect on MMSE, 2.) the inclusion criteria may 
have been too broad (a MMSE score of 12-26 will include mildly and severely 
impaired patients, and 3.) the dose of 50 mg/kg of NAC was likely not high 
enough to show an effect. It may be possible for a potent thiol antioxidant with 
better brain penetration to show an effect in a well-designed study of AD. 
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5.2.2 NACA in Parkinson disease 
 
As discussed earlier, the symptoms of Parkinson disease are due, at least in  
part, to the loss of dopaminergic neurons in the substantia nigra. It is believed 
that oxidative stress plays an important role in dopaminergic neuron loss. Animal 
models for PD commonly utilize toxins (6-hydroxydopamine (6-OHDA), 1-methyl- 
4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) and rotenone) to selectively destroy 
dopaminergic neurons. These toxins are also known to produce oxidative stress. 
A study by Bahat-Stroomza et al investigated the neuroprotective effects of  
NACA in three animal models of PD: 1.) amphetamine-induced rotational 
behavior in unilateral 6-OHDA-induced nigral lesioned rats, 2.) MPTP treated 
mice, and 3.) rotenone treated rats.248  In the 6-OHDA rat model, 120mg/kg 
NACA or saline was administered intraperitoneally (i.p.) 15 minutes before the 6- 
OHDA lesion. The rats were allowed to recover for 14 days and then 
amphetamine-induced rotations were counted for 2 hours following  
administration of amphetamine 5mg/kg i.p. The intensity of the amphetamine- 
induced rotation is directly proportional to the extent of the unilateral 6-OHDA 
nigral lesions.249 In this rat model, NACA treatment markedly reduced 
amphetamine-induced rotations by 49% (p<0.001). 
 
 
In the MPTP model, C57/bL mice were administered 25 mg/kg MPTP i.p. once 
daily for 5 consecutive days.  During the 5-day treatment period, NACA 
1g/kg/day was administered in drinking water. At the end of the 5-day treatment 
period striatal dopamine levels were measured. MPTP treatment reduced striatal 
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dopamine content by 51% compared with control mice (p<0.05). Administering 
NACA in drinking water during the 5-day treatment period with MPTP almost 
completely prevented the MPTP induced reduction in striatal dopamine content. 
In the rotenone model, rats were administered rotenone 5mg/kg/day for 28 days 
intravenously. During the 28-day treatment period, NACA, 100mg/kg/day was 
administered in drinking water. At the end of the treatment period nigral 
dopaminergic neurons were counted. Chronic (28-day) daily administration of 
rotenone markedly reduced dopaminergic neurons in these rats. However, 
administering NACA in the drinking water during the 28-day treatment period 
completely abolished the rotenone induced reduction in dopaminergic neurons. 
In this study, NACA demonstrated marked activity in three independent animal 
models of PD. These consistent results across animal models suggest that 
NACA may be beneficial for the treatment of PD. 
 
 
5.2.3 NACA in Multiple Sclerosis 
 
Multiple sclerosis (MS) is a chronic, progressive autoimmune disease targeting 
the white and gray matter of the brain and spinal cord. The autoimmune 
response causes inflammation, demyelination and nerve cell death.  Currently 
there is no cure for MS; therefore treatment is focused on improving the quality of 
life and reducing the symptoms of the disease.  Reactive oxygen species have 
been implicated as mediators of demyelination and nerve cell death in MS. It is 
known that oxidative stress activates certain transcription factors involved in MS, 
for example nuclear factor kappa B (NF-κB) which up-regulate the expression of 
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many cell factors involved in MS including tumor necrosis factor α (TNFα). 
Therefore, because of the role of oxidative stress in MS, it seems reasonable that 
antioxidants may provide a treatment option.  In the model of experimental 
autoimmune encephalomyelitis (EAE), a well-accepted mouse model of MS, 
several studies have demonstrated the protective effects of antioxidants and 
suppression of EAE. Although a number of antioxidants have been studied 
clinically in neurodegenerative disorders, little benefit has been observed, 
presumably due to the limited penetration of these antioxidants into the CNS. Due 
to the proposed increased brain penetration of NACA, Offen et al studied NACA 
in the EAE mouse model of MS to characterize the ability of NACA to      
penetrate the brain, its antioxidant properties and its effects on motor function.245 
 
 
NACA and NAC were administered intraperitoneally, 30mg/kg, and orally 
160mg/kg to mice.  Fifteen minutes after study drug administration the mice were 
sacrificed and NACA and NAC concentrations in the brain were determined. 
Following both i.p. and oral NACA administration, significant NACA 
concentrations could be detected in the mouse brains. In contrast, following oral 
and i.p. NAC administration, NAC could not be detected in the mouse brains, 
although an increase in cysteine was detected after NAC administration. 
 
 
The ability of NACA and NAC to replenish GSH and prevent protein oxidation 
was also tested in human red blood cells (hRBCs). In GSH depleted hRBCs, 
both NACA and NAC increased the RBC thiol content (GSH + other thiols), 
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however NACA was more effective than NAC (220% versus 62% respectively at 
5mM conc). The addition of tert-butylhydroxyperoxide (t-BHP) to hRBCs 
increased ROS and caused progressive loss of intracellular thiols and an 
increase in oxidized hemoglobin. In contrast, in hRBCs pretreated with NACA 
(5mM) prior to exposure to tBHT, intracellular thiol levels increased and normal 
levels of oxidized hemoglobin were observed, indicating the NACA protected the 
nRBCs from oxidative stress. Interestingly, a sharp decrease in intracellular 
thiols and an increase in oxidized hemoglobin were observed in hRBCs pre- 
treated with NAC (5mM) prior to tBHT exposure. The authors concluded that 
NACA is approximately threefold more efficient than NAC at restoring 
intracellular thiol pools, probably due to the better penetration into the cell. They 
also stated that “unlike NAC, NACA appeared to integrate into the redox 
machinery of the human RBC and effectively protect hemoglobin from 
oxidation.”244 
 
 
The EAE mouse model has many clinical and pathological similarities to human 
MS 250,251; therefore this model was utilized to test NACA effects on motor 
function and development EAE. Initial in vivo experiments were performed to test 
the efficacy of NACA to suppress EAE when given orally in varying doses (5-50 
mg/kg) twice daily.  All mice that received only saline developed clinical signs 
while the NACA-treated mice showed a marked delay in the onset and a 
significant reduction in the severity of the clinical EAE signs. The next 
experiments explored the efficacy of NACA after the appearance of clinical signs. 
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EAE was induced in the mice by immunization on Day 1 and Day 8 with an 
emulsion containing myelin oligodendrocyte glycoproteins (MOG). Clinical 
symptoms of EAE developed within 14-18 days in the majority of animals.  Mice 
were randomly assigned to one of four treatment groups: 1) control (daily saline 
administration), 2.) daily 200 mg/kg NACA i.p. from the first MOG injection, 3.) 
daily 200mg/kg NACA i.p.from Day 8 after the first MOG injection and 4.) daily 
200mg/kg i.p. from day 14 after the first MOG injection (when the first EAE 
symptoms typically appear). At several time points following the first MOG 
injection, the mice were scored for EAE clinical signs: 0=no paralysis, 1=loss of 
tail tonicity, 2=mild hind limb weakness, 3=complete hind limb paralysis, 
4=paralysis of four limbs, 5=total paralysis and 6=death. 
 
 
In the EAE mouse model of MS, NACA administered from Day 1, Day 8, or Day 
14 following the initial MOG injection was highly effective (p<0.002 compared to 
control) at reducing EAE clinical score. In addition, when NACA was 
administered after the appearance of symptoms on Day 14 following the initial 
MOG injection, a marked improvement (p<0.002 compared to control) in EAE 
clinical score was observed.  Consistent with these reductions in clinical score, 
reduced inflammation and absence of inflammatory cells were observed in spinal 
cords from NACA-treated mice compared with control, saline-treated mice. 
 
 
These studies indicate that NACA may have promise as an antioxidant in 
neurodegenerative disorders, and that it may be a more potent antioxidant, with 
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increased ability to penetrate the blood brain barrier and cell membranes than 
NAC, at concentrations that are non-toxic. 
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Chapter 6 
Conclusion 
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Neurodegenerative disorders such as Alzheimer’s disease, Parkinson disease 
and multiple sclerosis are common disorders affecting millions in the U.S. alone. 
While treatments are currently available, they are symptomatic treatments, as 
cures for these disorders remain elusive. Other neurodegenerative disorders 
such as adrenoleukodystrophy, Huntington’s disease and amyotrophic lateral 
sclerosis, although less common, are devastating disorders with variably 
effective treatments and no cure.  All of these disorders share a common 
element involved in their pathogenesis and/or progression: oxidative stress. 
 
 
Oxidative stress is generated in neurons when the metabolic balance is 
overwhelmed and the sum of free radicals generated by oxygen metabolism is 
greater than the capacity of the cell to detoxify these substances. Oxidative 
stress is common in the brain, as it uses a disproportionate amount of oxygen 
per volume of tissue compared to other organs.1   Glutathione (GSH) is the most 
prevalent endogenous antioxidant in the brain. It exerts its antioxidant effects 
non-enzymatically by reacting with superoxide7, nitric oxide (NO) 8 hydroxyl 
radicals9, and peroxynitrite (ONOO-).10 GSH also serves as an electron donor for 
the reduction of H2O2 or other peroxides catalyzed by GPx.12 The ratio of 
reduced to oxidized glutathione (GSH/GSSG) serves as an indicator of the 
cellular redox environment.14 GSH also serves as a non-toxic form of cysteine 
storage,16 a major redox buffer,17 and a neurotransmitter/neuromodulator.18 
Since GSH is the most important antioxidant in the brain, its depletion is an 
important factor in the pathogenesis of many neurodegenerative disorders; 
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whether GSH depletion is a cause or one of the effects of disease is still in 
question. 
 
 
Since the search for a cure for most neurodegenerative disorders is ongoing, 
trials of antioxidants that could slow the progression or perhaps ultimately 
prevent these disorders is a worthwhile endeavor.  Several  antioxidants, 
including vitamin C and E, Co-enzyme Q-10, and even glutathione itself have 
been studied in Parkinson’s, Alzheimer’s and Huntington’s disease, 
 
 
MS and other neurologic disorders without much success, due to their inability to 
effectively cross cellular membranes and the blood brain barrier.  N- 
acetylcysteine (NAC) is a thiol antioxidant that has been tested in the clinical 
setting for a variety of disorders characterized by oxidative stress, due to its 
efficiency in synthesis and replenishment of GSH in addition to its ability to 
scavenge reactive oxygen species (ROS). Besides antioxidant activity, NAC 
exerts numerous key pharmacological actions. NAC reduces disulfide bonds that 
crosslink glycoproteins in mucus and thus acts as mucolytic agent. It exhibits 
anti-inflammatory properties by inhibiting NF- κ B activation. It is also a chelator 
of heavy metals including mercury, lead, and arsenic. It acts as a precursor of 
glutamate which plays a major role in the neurobiology of mood, psychosis, and 
addiction. Further, NAC has been considered as cardioprotectant as it decreases 
the elevated levels of homocysteine. Furthermore, NAC has also been shown to 
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play a major role in vasodilation, neutrophil activation, and microbial attachment, 
and interferes with redox signaling.252,253 
 
 
The studies reported in this thesis include a pharmacokinetic study of NAC in 
young boys with X-linked adrenoleukodystrophy undergoing hematopoietic stem 
cell transplant, and a pharmacokinetic/pharmacodynamics study of NAC in adult 
patients with Parkinson’s disease and Gaucher disease. In the first study, my 
research colleagues and I report for the first time, the pharmacokinetic 
parameters of NAC in pediatric patients and assess the effect of HSCT and the 
pre and post- transplant immunosuppressants on NAC PK parameters. In the 
second study we report, also for the first time, the direct effects of NAC 
administered intravenously on brain glutathione concentrations.  Both of these 
preliminary studies add to our knowledge of the pharmacokinetics of NAC and its 
effects on brain GSH concentrations and should assist with design of larger, 
placebo-controlled trials of NAC in neurodegenerative disorders. What is yet to 
be determined in a well-designed trial, is whether orally administered NAC would 
have similar effects on brain GSH. 
 
 
Although NAC has become a researcher’s preferred antioxidant to treat various 
pathologies associated with oxidative stress, and has shown beneficial effects in 
experimental animals and some clinical trials, few clinical trials have shown a 
robust effect of NAC and it is still only used routinely in acetaminophen overdose 
and as a mucolytic agent. The failure of NAC to show significant effect may be 
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due to its low bioavailability and hydrophobicity. At physiological pH, NAC 
acquires a negative charge by losing a proton from the carboxyl group. This 
deprotonation hinders its passage across the biological membrane.243 In a critical 
oxidative stress condition, the concentration of NAC may not be enough to 
replenish the intracellular GSH content. Moreover, a few studies have 
demonstrated the pro-oxidant nature of NAC at higher concentrations.244 
 
 
In spite of these limitations, the use of thiol antioxidants in clinical settings is 
warranted to counteract the excess ROS. Following systemic delivery, the drug 
has to reach the target site in a steady-state concentration. In this regard, 
antioxidant compounds with better membrane permeability may become vital 
molecules to target the site of excess ROS production, especially the brain. One 
such potential molecule is N-acetylcysteine amide (NACA), a derivative of NAC 
in which the carboxyl group is neutralized by an amino group.  NACA has been 
shown to cross the blood-brain barrier as well as other biological membranes 
more effectively than NAC.  Additionally, NACA has been shown to be effective 
in several animal models of neurodegenerative disease, including models of 
Parkinson’s disease and multiple sclerosis. 
 
 
The research included in this thesis lays the groundwork for future studies of 
NAC and its derivative NACA in the potential treatment of neurodegenerative 
disorders which include critical levels of oxidative stress and glutathione 
depletion.  Until such time as a cure is discovered, hopefully compounds such as 
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these can bring symptom relief and hope to those who suffer from the 
devastating effects of disorders such as Parkinson disease, Gaucher disease, 
and particularly adrenoleukodystrophy. 
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